

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization  
International Bureau



(43) International Publication Date  
18 April 2002 (18.04.2002)

PCT

(10) International Publication Number  
**WO 02/30866 A1**

(51) International Patent Classification<sup>7</sup>: C07C 203/04,  
233/54, 323/60, C07D 201/02, C07C 317/46, A61K 31/21,  
C07D 213/34, A61K 31/44

(74) Agents: SAMA, Daniele et al.; Sama Patents, Via G.B.  
Morgagni, 2, I-20129 Milano (IT).

(21) International Application Number: PCT/EP01/11664

(81) Designated States (*national*): AE, AG, AL, AU, BA, BB,  
BG, BR, BZ, CA, CN, CR, CU, CZ, DM, DZ, EE, GD, GE,  
HR, HU, ID, IL, IN, IS, JP, KP, KR, LC, LK, LR, LT, LV,  
MA, MG, MK, MN, MX, NO, NZ, PL, RO, SG, SI, SK,  
TR, TT, UA, US, UZ, VN, YU, ZA.

(22) International Filing Date: 9 October 2001 (09.10.2001)

(25) Filing Language: English

(84) Designated States (*regional*): ARIPO patent (GH, GM,  
KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW), Eurasian  
patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European  
patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE,  
IT, LU, MC, NL, PT, SE, TR), OAPI patent (BF, BJ, CF,  
CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD,  
TG).

(26) Publication Language: English

(30) Priority Data:  
MI2000A002202 12 October 2000 (12.10.2000) IT

(71) Applicant (*for all designated States except US*): NICOX  
S.A. [FR/FR]; 2455, route des Dolines, Espace Gaia II -  
Bâtiment I, F-06906 Sophia Antipolis Cedex (FR).

**Published:**

- with international search report
- before the expiration of the time limit for amending the  
claims and to be republished in the event of receipt of  
amendments

(72) Inventors; and

(75) Inventors/Applicants (*for US only*): DEL SOLDATO,  
Piero [IT/IT]; Via Toti, 22, I-20052 Monza (IT). BENE-  
DINI, Francesca [IT/IT]; Via Padova, 286, I-20100 Mi-  
lano (IT). ANTOGNAZZA, Patrizia [IT/IT]; Via G.B.  
Morgagni, 10, I-20100 Milano (IT).

*For two-letter codes and other abbreviations, refer to the "Guid-  
ance Notes on Codes and Abbreviations" appearing at the begin-  
ning of each regular issue of the PCT Gazette.*



**WO 02/30866 A1**

(54) Title: NITRODERIVATIVES AS DRUGS FOR DISEASES HAVING AN INFLAMMATORY BASIS

(57) Abstract: Use for the treatment of diseases having an inflammatory basis of compounds or salts thereof, having the following general formula (I): A-X<sub>1</sub>-L-(W)<sub>p</sub>-NO<sub>2</sub> wherein A contains the radical of a drug, X<sub>1</sub> and W are bivalent radicals, L is a covalent bond or oxygen, sulphur, NR<sub>1c</sub> wherein R<sub>1c</sub> is H or a C<sub>1</sub>-C<sub>3</sub> linear or branched alkyl.

## NITRODERIVATIVES AS DRUGS FOR DISEASES HAVING AN INFLAMMATORY BASIS

\* \* \* \* \*

The present invention relates to compounds and the use thereof for diseases affecting the digestive apparatus, in particular the intestinal tract, specifically colites, gastrites, enterites, duodenites and hepatopathies of various nature (on a viral, immune, dismetabolic basis due to intoxications from drugs such as paracetamol and other analgesic, antibiotic, antitumoural, antidepressive drugs, etc., alcohol, etc.).

The digestive apparatus diseases are very diffused. While the therapy of the peptic ulcer has generally reached efficacy, the same cannot be said for other diseases affecting the digestive apparatus. For example it is known that yearly in the Unites States more than 25 million people suffer diseases affecting liver and gall-bladder and more than 26,000 people die owing to chronic hepatopathies and cirrhosis. Generally the therapeutical treatment is widely unsatisfactory. Among the compounds used for these treatments interferon  $\alpha$ -2b can be mentioned, which allows the recovery in about 30-40% of the cases affected by chronic hepatitis B and 20-25% of those affected by chronic hepatitis C.

However the interruption of the treatment causes a recidivism in 50-80% of the patients. Only 10% of the cases of hepatitis B are satisfactory with interferon  $\alpha$ -2b. Another compound used for these pathologies is ribavirin, however the efficacy is not yet well known. Other used compounds are vaccines, which however are used only in the prophylaxis.

For the cirrhosis treatment there are generally no

effective compounds. At present the treatment is above all of support and it can consist in a suitable diet, alcohol abstinence or in the administering of diuretics or vitamins.

The therapeutic treatment is generally unsatisfactory for the diseases affecting the intestinal tract such colites, duodenites, enterites. For example the therapy with 5-amino salicylic acid and derivatives thereof is not fully effective. The use of steroidal compounds (for example prednisolone and the like) can cause toxic symptoms or serious side effects.


It must be added that generally the pathologies on an inflammatory basis, such as those above described affecting the digestive apparatus, are considered precancerous forms, since they can evolve into tumoural processes. In the same way for the pathologies on an inflammatory basis, which can concern different systems such the urogenital, respiratory apparatuses, the skin districts, etc.

Therefore the treatment of these pathologies of inflammatory nature has a critical importance also in the prevention and in the treatment of tumoral diseases.

The need was felt to have available compounds active in diseases on an inflammatory basis, in particular those affecting the digestive apparatus and for the prevention and/or treatment of the tumoral processes related to the above diseases.

It has been surprisingly found by the Applicant that it is possible to solve the above technical problem with specific nitroderivatives as described hereunder.

An object of the present invention is the use, for diseases on an inflammatory basis, of nitroderivatives or salts thereof having the following general formula (I):




wherein:

p is an integer equal to 1 or 0;

A = R-T<sub>1</sub><sup>-</sup>, wherein

R is the radical of a precursor drug and it has the following formulas:



(AI)


s is an integer and is 1 or 0;

R<sub>AI</sub> is H, CH<sub>3</sub>;

R<sub>1</sub> is OCOR<sub>3</sub>, R<sub>3</sub> being a C<sub>1</sub>-C<sub>5</sub> linear or branched radical, NHCOR<sub>3</sub>, wherein R<sub>3</sub> has the above meaning, or R<sub>1</sub> is OH, CH<sub>2</sub>CH(CH<sub>3</sub>)<sub>2</sub>, phenyl, benzoyl, 4,6-dichlorophenylamino;


R<sub>6</sub> is H, or an halogen atom, preferably fluorine;

or R<sub>1</sub> and R<sub>6</sub>, when are located in the adjacent positions 4 and 5 of the aromatic ring of formula (AI), form the radical of following formula (AIa):



(AIa)

or R can be the following formula:



(AII)

$T_1 = (CO)_t$  or  $(X)_{t'}$ ; wherein  $X = O, S, NR_{1c}, R_{1c}$  is H or a linear or branched alkyl having from 1 to 5 carbon atoms,  $t$  and  $t'$  are integers and equal to zero or 1, with the proviso that  $t = 1$  when  $t' = 0$ ;  $t = 0$  when  $t' = 1$ ;


$X_1 = -T_B-Y-T_{BI}-$  wherein

$T_B$  and  $T_{BI}$  are equal or different;

$T_B = (CO)$  when  $t = 0$ ,  $T_B = X$  when  $t' = 0$ ,  $X$  being as above;

$T_{BI} = (CO)_{tx}$  or  $(X)_{txx}$ , wherein  $tx$  and  $txx$  have the 0 or 1 value; with the proviso that  $tx = 1$  when  $txx = 0$ ; and  $tx = 0$  when  $txx = 1$ ;  $X$  is as above;

$Y$  is a bivalent linking group selected from the following:



(II)

wherein:

$nIX$  is an integer in the range 0-3, preferably 1;

$nIIX$  is an integer in the range 1-3, preferably 1;


$R_{TIX}, R_{TIX'}, R_{TIIX}, R_{TIIX'}$ , equal to or different from each other are H or a  $C_1-C_4$  linear or branched alkyl; preferably  $R_{TIX}, R_{TIX'}, R_{TIIX}, R_{TIIX'}$  are H;

$Y^3$  is a saturated, unsaturated or aromatic heterocyclic ring having 5 or 6 atoms, containing one or two nitrogen atoms,

an alkylene group  $R'$  wherein  $R'$  is a  $C_1-C_{20}$  linear or branched when possible, preferably


having from 2 to 6 carbon atoms, optionally substituted with one or more of the following groups:  $\text{-NHCOR}_3$ , wherein  $R_3$  is as above,  $\text{-NH}_2$ ,  $\text{-OH}$  or

- a cycloalkylene having from 5 to 7 carbon atoms, optionally substituted with side chains  $R'$ ,  $R'$  being as above, one or more carbon atoms of the cycloalkylene ring can optionally be substituted by heteroatoms; or




(III)

wherein  $n_3$  is an integer from 0 to 3 and  $n_{3'}$  is an integer from 1 to 3;



(IV)

wherein  $n_3$  and  $n_{3'}$  have the above meaning,




(V)

wherein


$R_4$  is hydroxy, hydrogen,  $R_5\text{O-}$  alkoxy wherein  $R_5$

is a C<sub>1</sub>-C<sub>10</sub> linear or branched or cyclic alkyl group, preferably R<sub>5</sub> is a methyl group;


R<sub>2</sub> is a C<sub>2</sub>-C<sub>10</sub> linear or branched alkenylene group which can contain one or more double bonds, preferably R<sub>2</sub> is the ethenylene group (-CH=CH-); or




(VI)



(VII)



(VIII)



(IX)

wherein  $R_{1f} = H, CH_3$  and  $nf$  is an integer from 0 to 6; preferably from 0 to 4;

$L =$  covalent bond, or  $L = X$ ,  $X$  being as above, or  $L = CO$ ;

$W = Y_rO$  wherein  $Y_r$  has the same meanings of  $Y$  but in the compound of formula (I)  $Y_r$  is equal to or different from  $Y$ . Preferably  $Y_r$  is different from  $Y$ .

The diseases on an inflammatory basis are those particularly affecting the digestive apparatus, preferably the intestinal tract, such as for example colites, gastrites, enterites, duodenites; besides epatopathies and tumoral processes related to diseases on an inflammatory basis.

When in formula (AI),  $R_1$  is an acetyloxy group in position 2 of the ring,  $s = 0$  and  $R_6 = H$  and the free valence of the radical  $R$  is saturated with the  $-COOH$  group, the compound is known as Acetylsalicylic Acid,

when in formula (AI)  $R_1$  is an hydroxyl group in position 2 of the ring,  $s = 0$  and  $R_6 = H$  and the free valence of the radical  $R$  is saturated with a  $-COOH$  group, the compound is known as Salicylic Acid,

when in formula (AI)  $R_1$  is an acetylamino group in position 4 of the ring,  $s = 0$  and  $R_6 = H$  and the free valence is saturated with an  $-OH$  group, the compound is known as Paracetamol,

when in formula (AI)  $R_1$  is  $CH_2CH(CH_3)_2$  in position 4 of the ring,  $s = 1$ ,  $R_{At} = CH_3$  and  $R_6 = H$  and the free valence is saturated with a  $-COOH$  group, the compound is known as Ibuprofen,

when in formula (AI)  $R_1$  is phenyl and it is in position 4 of the ring,  $s = 1$ ,  $R_{At} = CH_3$  and  $R_6 = F$  in position 3 and the free valence is saturated with a  $-COOH$  group, the compound is known as Flurbiprofen,

when in formula (AII) the free valence is saturated with the  $-COOH$  group, the compound is known as Sulindac;






when in formula (AI)  $R_1$  and  $R_6$  are the radical of formula (AIa) and they are connected with the positions 4 and 5 of the ring,  $s = 1$ ,  $R_{AI} = CH_3$ ,  $R_6 = H$  and the free valence is saturated with a  $-COOH$  group, the compound is known as Naproxen;

when in formula (AI)  $R_1$  is a benzoyl radical in position 5 of the aromatic ring,  $s = 1$ ,  $R_{AI} = CH_3$ ,  $R_6 = H$  and the free valence is saturated with a  $-COOH$  group, the compound is known as Ketoprofen;

when in formula (AI)  $R_1 = 2,6$ -diclorofenilammino in position 2 of the ring,  $s = 1$ ,  $R_{AI} = H$ ,  $R_6 = H$  and the free valence is saturated with a  $-COOH$  group, the compound is known as Diclofenac.

Preferably  $Y^3$  in formula (II) of the linking group  $Y$  of  $X_1$  in formula (I) is selected from the following bivalent radicals:



Preferably  $Y^3$  is an aromatic ring having 6 atoms, containing one nitrogen atom, said aromatic ring having the

two free valences respectively in the positions 2 and 6, or 2 and 3 or 2 and 5 with respect to the heteroatom.

The preferred of  $Y^3$  is Y12 (pyridyl) substituted as above indicated. The bonds can also be in an unsymmetrical position, for example Y12 (pyridyl) can be substituted also in position 2 and 3; Y1 (pyrazol) can be 3,5-disubstituted.

The preferred compounds are those wherein in formula (I):

- when in formula (AI)  $s = 0$  and  $R_6 = H$ :

- R is a radical of formula (AI) wherein the substituent  $R_1$  is in position 2 of the aromatic ring, and it is selected between acetyloxy or hydroxyl, or it is an acetylamino group and then it is in position 4;  $-T_1-T_3-$  is a  $-CO-O-$  or  $-O-OC-$  ester group; Y of the radical  $X_1$  is a bivalent linking group selected from the following:

- a radical of formula (III) as above, wherein  $n_3 = 0$  and  $n_3' = 1$ ,
- a radical of formula (II) as above wherein  $Y^3$  is Y12 as above defined,
- a radical of formula (VIII) as above wherein  $R_{1f}$  is hydrogen and  $n_f = 1$ ;

$T_{B1} = -O-$ , L = covalent bond;  $p = 0$ ;

- R is a radical of formula (AI) wherein the substituent  $R_1$  is in position 2 of the aromatic ring, and it is selected between acetyloxy or hydroxyl, or it is an acetylamino group and then it is in position 4;  $-T_1-T_3-$  is a  $-CO-O-$  or  $-O-OC-$  ester group; Y of the radical  $X_1$  is a bivalent linking group having formula (V) as above wherein  $R_4$  is a methoxyl group and  $R_2 = -CH=CH-$ ;  $-T_{B1}-L-$  is a  $-CO-O-$  or  $-O-OC-$  ester group;  $p = 1$ ;  $W = YO$  wherein Y is  $-(CH_2)_4-$  or  $-(CH_2)_3-$ ;

- R is a radical of formula (AI) wherein the substituent  $R_1$  is in position 4 of the aromatic ring, and it is acetylamino;  $-T_1-T_B-$  =  $-O-CO-$ ; Y of the radical  $X_1$  is  $-(CH_2)_3-$ ;  $-T_{B1}-L-$  =  $-O-$  (L = covalent bond);  $p = 0$ ;
- R is a radical of formula (AI) wherein the substituent  $R_1$  is in position 4 of the aromatic ring, and it is acetylamino;  $-T_1-T_B-$  =  $-O-CO-$ ; Y of the radical  $X_1$  is an ethylene group substituted with an acetylamino group:  $-CH(NHCOCH_3)-CH_2-$ ;  $-T_{B1}-L-$  =  $-S-CO-$ ;  $p = 1$ ;  $W = YO$  wherein Y is  $-(CH_2)_3-$ ;
- when in the formula (AI)  $s = 1$ :
  - R is a radical of formula (AI),  $R_6 = H$  or  $F$  in position 3 of the ring,  $R_1 = CH_2CH(CH_3)_2$  or phenyl in position 4,  $-T_1-T_B-$  is a  $-CO-O-$  ester group; Y of the radical  $X_1$  is a bivalent linking group having formula (V) as above wherein  $R_4$  is a methoxyl group and  $R_2 = -CH=CH-$ ;  $-T_{B1}-L-$  is a  $-CO-O-$  ester group;  $p = 1$ ;  $W = YO$  wherein Y is  $-(CH_2)_3-$ ;
  - when in formula (I) R is a radical of formula (AII),  $-T_1-T_B-$  =  $-CO-O-$ ; Y of the radical  $X_1$  is a bivalent linking group selected from the following:
    - a radical of formula (II) as above wherein  $Y3$  is  $Y12$  as above,
    - $-(CH_2)_4-$ ;
    - $-T_{B1}-$  =  $-O-$ , L = covalent bond;  $p = 0$ .

The preferred compounds according to the present invention are those wherein:

- the drug radical has formula (AI) and the compounds of formula (I) are the following:
  - 2-(acetyloxy)benzoic acid 3-(nitrooxymethyl)phenyl ester,
  - 2-(hydroxy)benzoic acid 3-(nitrooxymethyl)phenyl ester,
  - 2-(acetyloxy)benzoic acid 4-(nitrooxymethyl)phenyl ester,

2-(hydroxy)benzoic acid 4-(nitrooxymethyl)phenyl ester,  
2-(acetyloxy)benzoic acid 2-(nitrooxymethyl)phenyl ester,  
2-(hydroxy)benzoic acid 2-(nitrooxymethyl)phenyl ester,  
2-(acetyloxy)benzoic acid 6-(nitrooxymethyl)-2-methyl pyri-  
diny ester hydrochloride, or nitrate,  
2-(hydroxy)benzoic acid 6-(nitrooxymethyl)-2-methyl pyridiny  
ester hydrochloride, or nitrate,  
2-(acetyloxy)benzoic acid 5-(nitrooxymethyl)-2-methyl pyri-  
diny ester hydrochloride, or nitrate,  
2-(hydroxy)benzoic acid 5-(nitrooxymethyl)-2-methyl pyridiny  
ester hydrochloride, or nitrate,  
2-(acetyloxy)benzoic acid 3-(nitrooxymethyl)-2-methyl pyri-  
diny ester hydrochloride, or nitrate,  
2-(hydroxy)benzoic acid 3-(nitrooxymethyl)-2-methyl pyridiny  
ester hydrochloride, or nitrate,  
trans-3-[4-[2-acetyloxybenzoyloxy]-3-methoxyphenyl]-2-prope-  
noic acid 4-(nitrooxy)butyl ester,  
trans-3-[4-[2-hydroxybenzoyloxy]-3-methoxyphenyl]-2-propenoic  
acid 4-(nitrooxy)butyl ester,  
4-(nitrooxy)butanoic acid 4-(acetylamino)phenyl ester,  
trans-3-[4-(4'-nitrooxybutyryloxy)-3-methoxyphenyl]-2-prope-  
noic acid 4-(acetylamino)phenyl ester,  
3-(nitrooxymethyl)-benzoic acid 4-(acetylamino)phenyl ester,  
4-(nitrooxymethyl)-benzoic acid 4-(acetylamino)phenyl ester,  
2-(nitrooxymethyl)-benzoic acid 4-(acetylamino)phenyl ester,  
5-(nitrooxymethyl)pyridin-2-carboxylic acid 4-(acetyl ami-  
no)phenyl ester,  
6-(nitrooxymethyl)-pyridin-2-carboxylic acid 4-(acetyl ami-  
no)phenyl ester,  
3-(nitrooxymethyl)-pyridin-2-carboxylic acid 4-(acetyлами-  
no)phenyl ester,  
5-(nitrooxymethyl)-pyridin-2-carboxylic acid 4-(acetyлами-  
no)phenyl ester,

5-(nitrooxymethyl)pyridin-2-acetic acid 4-(acetylamino)phenyl ester,

6-(nitrooxymethyl)pyridin-2-acetic acid 4-(acetylamino)phenyl ester,

3-(nitrooxymethyl)pyridin-2-acetic acid 4-(acetylamino)phenyl ester,

3-[(2-nitrooxy)ethyloxy]propanoic acid 4-(acetylamino)phenyl ester,

trans 3-[4-(4'-nitrooxybutyryloxy)-3-methoxy]phenyl-2-propenoic acid 4-(acetylamino)phenyl ester,

2-(acetylamino)-3-(4-nitrooxybutyryl)-3-mercaptopropanoic acid 4-(acetylamino)phenyl ester,

trans-3-[4-[ $\alpha$ -methyl-4-(2-methylpropyl)phenylacetyloxy]-3-methoxyphenyl]-2-propenoic acid 4-nitrooxybutyl ester,

trans 3-[4-[2-fluoro- $\alpha$ -methyl(1,1'-biphenyl)-acetyloxy]-3-methoxyphenyl]-2-propenoic acid 4-nitrooxybutyl ester,

(S) 6-methoxy- $\alpha$ -methyl-2-naphtalenacetic acid 2-methoxy-4-[(1E)-3-[4-(nitrooxy)butoxy]-3-oxo-1-propenyl]phenyl ester,

(S) 6-methoxy- $\alpha$ -methyl-2-naphtalenacetic acid 3-(nitrooxymethyl)phenyl ester,

(S) 6-methoxy- $\alpha$ -methyl-2-naphtalenacetic acid 6-(nitrooxymethyl)-2-methylpyridinyl ester,

(S,S)-N-acetyl-S-(6-methoxy- $\alpha$ -methyl-2-naphtaleneacetyl)cysteine 4-(nitrooxy)butyl ester,

2-[(2,6-dichlorophenyl)amino]benzeneacetic acid 6-(nitrooxymethyl)-2-methylpyridinyl ester chloridrate,

The drug radical has formula AII and the compounds of formula (I) are the following:

(Z)-5-fluoro-2-methyl-1-[[4-(methylsulphinyl)phenyl] methylene]-1H-inden-3-acetic acid 4-(nitrooxy)butyl ester,


(Z)-5-fluoro-2-methyl-1-[[4-(methylsulphinyl)phenyl] methylene]-1H-inden-3-acetic acid 6-(nitrooxymethyl)-2-methylpyridinyl ester hydrochloride, or nitrate,

(Z)-5-fluoro-2-methyl-1-[[4-(methylsulphonyl)phenyl] methylene]-1H-inden-3-acetic acid 5-(nitrooxymethyl)-2-methylpyridinyl ester hydrochloride, or nitrate,


(Z)-5-fluoro-2-methyl-1-[[4-(methylsulphonyl)phenyl] methylene]-1H-inden-3-acetic acid 3-(nitrooxymethyl)-2-methylpyridinyl ester hydrochloride, or nitrate.

Other precursors of the general formula A = R-T<sub>1</sub>- wherein the free valence is saturated with -OH, that can be used for obtaining the compounds of formula (I) are the following:

(S)-Benzenepropanoic acid, 4-[2-(2-benzoxazolylmethyl amino)ethoxy]--(2-ethoxy) of formula (XX):




(S)-Benzenepropanoic acid, 4-[2-(2-benzoxazolylmethyl amino)ethoxy]--(2,2,2-trifluoroethoxy) of formula (XXI):




Compounds (XX) and (XXI) are described in PCT Patent Application WO 97/25042;

L-Tyrosine, N-(2-benzoylphenyl)-O-[2-(methyl-2-pyridinyl amino)ethyl] of formula (XXII):




The above compound is described in PCT Patent Application WO 97/31907;

Prosta-5,9,12,14-tetraen-1-oic acid, 11-oxo-, (5Z,12E,14E) (15-Deoxy  $\Delta$ 12,14-prostaglandin) of formula (XXIII):



(XXIII)

(2S,5S)-4-(4-(4-carboxyphenyl)butyl)-2-heptyl-4-oxo-5-thiazolidine N,N-dibenzylacetamide of formula (XXIV):



(XXIV)

The above compound is described in Proc. Natl. Acad. Sci 1999, 96(11), 6102-6106.

The bivalent radical precursors of formula (II) are for example those wherein the two free valences are saturated with two hydroxyl groups, or with one hydroxyl group and one carboxylic group. These compounds are available on the market.

When the drug radical R or the bivalent radical Y and/or W as above defined contain one or more asymmetric carbon atoms, the corresponding precursors can be used in the synthesis of the compounds of the invention both in racemic form and as single optical isomers.

When in the molecule of the compounds of the invention (formula I) a salifiable functional group, for example an amino or heterocyclic nitrogen is present, it is possible to use the corresponding salts. The latter are obtained by reaction in organic solvent such as for example acetonitrile,

tetrahydrofuran, with an equimolecular amount of the corresponding organic or inorganic acid.

Examples of usable organic acids are the following: oxalic, tartaric, maleic, succinic, citric acid.

Examples of usable inorganic acids are the following: nitric, hydrochloric, sulphuric, phosphoric acid. Nitric and hydrochloric acid are preferred.

The compounds of the invention, as said, develop a marked protective action towards hepatopathies and in general towards diseases affecting the digestive apparatus, in particular the intestinal tract, in particular colites, gastrites, enterites, duodenites and hepatopathies. It has been found that the compounds of the invention in comparison with native precursors not only are not toxic as to the digestive apparatus, but unexpectedly they are able to prevent or reduce the diseases affecting this apparatus. For example the paracetamol efficacy as analgesic is known, however this compound causes damages at hepatic level (hepatic toxicity). The paracetamol nitrooxy derivatives according to the invention, besides being effective analgesic drugs, have no hepatic toxicity, but they are also able to prevent or reduce already existing hepatic damages.

The results obtained with the compounds of the invention are still more surprising if one considers that by using another NO donor such for example sodium nitroprussiate in pathologies affecting the digestive apparatus, there is no protection, on the contrary an hepatic damage occurs. Besides, this drug causes high hypotension.

As said, the compounds of the invention have a beneficial action also on tumoral processes, when used in the prophylaxis or in the therapy. As said, the pathologies on an inflammatory basis are considered precancerous forms, being able to subsequently evolve into tumoral processes. The pathologies on an inflammatory basis can involve various



systems such as the urogenital, respiratory, skin, digestive system, etc.

Therefore the treatment of these pathologies of inflammatory nature has a critical importance also in the prevention and in the treatment of tumoral diseases.

In the treatment of tumoral diseases the compounds of the invention can be used alone or in combination with known antitumoral treatments, such for example the administering of chemotherapeutic drugs, for example cis-platinum, adriamycin etc., or the radiotherapeutic treatment.

It has unexpectedly been found by the Applicant that the compounds of the invention, when used in combination with the above tumoral treatments, synergically enhance the therapeutic effect.

The administering of the compounds of the invention can be made contemporaneously with the chemotherapeutic or radiotherapeutic treatments, or previously or subsequently to the chemotherapeutic or radiotherapeutic treatments.

Preferably the compounds of the invention are used for the treatment and/or prevention of the tumoral process affecting the digestive apparatus. The preferred compounds are the above ones.

The compounds of the invention are prepared according to known methods of the prior art.

In general if in the drug molecule or in the molecules of the radicals Y and W more reactive groups such as for example COOH and/or HX are present, they must be protected before the reaction according to the known procedures of the prior art; for example as described in the volume by Th. W. Greene: "Protective groups in organic synthesis", Harward University Press, 1980.

Acyl halides are prepared according to known procedures of the prior art, for example by thionyl or oxalyl chloride,

halides of  $P^{III}$  or  $P^V$  in solvents inert under the reaction conditions, such for example toluene, chloroform, DMF, etc.

1) When in formula (I) L is a covalent bond and  $p = 0$ , and the free valence of the drug radical R is saturated with a carboxylic group, the synthesis methods for obtaining the corresponding nitrooxyderivatives are the following:



1.a) The acyl halide of the drug of formula  $R-CO-Cl$  is reacted with an halogenalcohol of formula  $HO-Y-Hal$ , wherein Y is as above and Hal is halogen (Cl, Br, I).




1.b) Alternatively, the reaction can be carried out by reacting the sodium or potassium salt of the drug with a dihalogen derivative of general formula  $Y(Hal)_2$ , wherein Y and Hal are as above defined.



1.c) Or the drug of formula  $RCOOH$  is treated with an agent activating the carboxyl selected from N,N'-carbonyl diimidazol (CDI), N-hydroxybenzotriazole and dicyclohexylcarbodiimide in solvent such for example, DMF, THF, chloroform etc. at a temperature in the range  $-5^\circ C$  to  $50^\circ C$  and reacted in situ with a compound  $HO-Y-Hal$ , wherein Y and Hal are as above defined.




1.d) Alternatively, the acyl halide of the drug is reacted with a compound  $HO-Y-OH$ , wherein Y is as above, in the presence of a base, in an organic solvent inert under the reaction conditions according to the scheme reported hereunder:





1.e) Alternatively to the previous syntheses the acyl halide of the drug is reacted with a compound  $HO-M-CHO$ , wherein M is an aromatic ring having 6 carbon atoms, or a radical

$Y^3$  as above, in the presence of a base, in an organic solvent inert under the reaction conditions according to the scheme reported hereunder:



The obtained compound is subjected to hydrogenation in the presence of palladium on carbon to give the corresponding alcohol:



wherein Y is as above defined.

- 1.f) When the products obtained in the above reactions have formula  $R-COO-Y-Hal$  the corresponding nitrooxyderivatives are obtained by reacting the compound  $R-CO-O-Y-Hal$  with  $AgNO_3$  in organic solvent such as acetonitrile, tetrahydrofuran according to the scheme:




- 1.g) When the compounds obtained in the above reactions have formula  $R-COO-Y-OH$  the corresponding nitrooxyderivatives can be obtained by treatment with fuming nitric acid in organic solvent under anhydrous conditions and in inert atmosphere, in the presence of an inorganic acid different from the nitric acid, or with an organic acid, or of an anhydride of one or two organic acids.
- 1.h) Alternatively, in the compound of formula  $R-COO-Y-OH$  the hydroxyl group is subjected to halogenation, for example, with  $PBr_3$ ,  $PCl_5$ ,  $SOCl_2$ ,  $PPh_3 + I_2$ , and then reacted with  $AgNO_3$  in organic solvent such as acetonitrile, tetrahydrofuran.
- 2) When in formula (I) L is a covalent bond and  $p = 0$ , and the free valence of the radical R of the drug is saturated with a hydroxyl group, the synthesis methods for obtaining the corresponding nitrooxyderivatives are the following:

- 2.a) By reaction of the drug of formula R-OH with an acyl halide of formula Hal-Y-COHal, wherein Y and Hal are as above, according to the scheme:





- 2.b) By reaction of the drug of formula R-OH with an acyl halide of formula OH-Y-COHal, wherein Y and Hal are as above, according to the scheme:



- 2.c) When the compounds obtained in the above reactions have formula R-OCO-Y-Hal or R-OCO-Y-OH the corresponding nitrooxyderivatives are obtained as described in 1.f and 1.h respectively.

3. When in formula (I)  $p = 1$  and  $L = X$ , wherein X is as above, or  $L = \text{CO}$ , and the free valence of the radical R of the drug is saturated with a carboxylic group, the synthesis methods for obtaining the corresponding nitrooxyderivatives are the following:

- 3.a) By reaction between the acyl halide of the drug and the compound of formula HX-Y-COOH, wherein X and Y are as above defined, according to the known methods of the prior art, to give the compound R-CO-X-Y-COOH which is transformed into the corresponding sodium salt and reacted with a compound of formula Hal-Y<sub>T</sub>-R<sub>8</sub> wherein Hal and Y<sub>T</sub> are as above and R<sub>8</sub> is Cl, Br, Iodine, OH:





If R<sub>8</sub> = OH the compound of formula (3.A') is subjected to halogenation as described in 1.h); if R<sub>8</sub> = Hal the compound of formula (3.A') is reacted with AgNO<sub>3</sub> in organic solvent such as acetonitrile, tetrahydrofuran:

- 3.b) When Y<sub>T</sub> is a C<sub>4</sub> linear alkylene, the acid of formula (3.A) is reacted with triphenylphosphine in the presence of an halogenating agent such as CBr<sub>4</sub> or N-

bromosuccinimide in tetrahydrofuran to give the compound of formula (3.A') wherein  $R_8 = \text{Br}$  which is transformed into the corresponding nitrooxyderivative as described in 1.h.

- 4) When in formula (I)  $p = 1$  and  $L = \text{X}$  or  $\text{CO}$ , and the free valence or the radical  $R$  of the drug is saturated with an hydroxyl group, the synthesis methods for obtaining the corresponding nitrooxyderivatives are the following:

- 4.a) Reaction of the drug of formula  $R\text{-OH}$  with an acyl halide of formula  $\text{HX-Y-COHal}$ , wherein  $X$  and  $Y$  are as above defined, according to the known methods of the prior art, to give the compound  $R\text{-O-CO-Y-XH}$  which is reacted with a compound of formula  $R_8\text{-Y}_T\text{-COHal}$  wherein  $R_8$  and  $Y_T$  are as above.



- 4.b) Alternatively, the drug of formula  $R\text{-OH}$  is reacted with a compound of formula  $\text{HX-Y-COOH}$ , wherein  $X$  and  $Y$  are as above, in the presence of dicyclohexylcarbodiimide as described in 1.c, to give the compound  $R\text{-O-CO-Y-XH}$ , which is reacted with a compound of formula  $R_8\text{-Y}_T\text{-COCl}$  wherein  $R_8$  and  $Y_T$  are as above defined to give the following compound:  $R\text{-O-CO-Y-X-CO-Y}_T\text{-R}_8$  (4.B).

When  $R_8 = \text{OH}$  the compound of formula (4.B) or of formula (4A') is subjected to halogenation as described in 1.h); if  $R_8 = \text{Hal}$  the compound of formula (4.B) is reacted with  $\text{AgNO}_3$  in organic solvent such as acetonitrile, tetrahydrofuran.

The compounds of the present invention are formulated in the corresponding pharmaceutical compositions for parenteral, oral and topical use according to the well known techniques in the field, together with the usual excipients; see for example the volume "Remington's Pharmaceutical Sciences 15a Ed."

The amount on a molar basis of the active principle in these formulations is the same, or lower, with respect to that used as antiinflammatory and/or analgesic drug of the corresponding precursor drug.


The daily administrable doses are those of the antiinflammatory and/or analgesic precursor drugs, or, in case, lower. The daily doses can be found in the literature of the field, such as for example in "Physician's Desk reference".

The following Examples illustrate the invention and they are not limitative of the scope of the same.

## EXAMPLES

### EXAMPLE 1

Synthesis of 2-acetyloxybenzoic acid 6-(nitrooxymethyl)-2-methylpyridinyl ester hydrochloride of formula:



A) Synthesis of 2,6-bis-(chloromethyl)pyridine

To thionyl chloride (11.6 ml, 158 mmoles), cooled at 0°C, 2,6-bis-(hydroxymethyl)pyridine (4 g, 28 mmoles) is added very slowly. The obtained solution is left under stirring for 2 hours at room temperature, then the thionyl chloride in excess is evaporated at a reduced pressure. The obtained residue is treated with chloroform and it is evaporated again at a reduced pressure to remove the thionyl chloride residues. The raw product is treated with chloroform and washed with water. The organic phase is anhydriified with sodium sulphate and dried obtaining 4,81 g of the product as white solid having melting point = 76-78°C.

B) Synthesis of 2-acetyloxybenzoic acid 6-(chloromethyl)-2-methylpyridinyl ester

To a solution of acetylsalicylic acid (1.6 g, 8.88 mmol) in N,N'-dimethylformamide (20 ml) and under stirring sodium ethylate (0.64 g, 8.88 mmol) is added. After 30 minutes the obtained solution is added to a solution of 2,6-bis-(chloromethyl)pyridine (4.72 g, 26.81 mmol) in N,N'-dimethylformamide (20 ml). The solution is left at room temperature for 7 days, under stirring, then it is diluted with ethyl ether and washed with water. The separated organic phases are anhydriified with sodium sulphate and the solvent is evaporated at a reduced pressure. The reaction raw product is purified by chromatography on silica gel eluting with n-hexane/ethyl acetate 7/3. 1.7 g of the product as yellow oil are obtained.

<sup>1</sup>H-NMR (200MHz)(CDCl<sub>3</sub>): 8.10(1H,d); 7.74(1H,t); 7.57(1H,t); 7.42(1H,d); 7.33(2H,m); 7.11(1H,d); 5.42(2H,s); 4.67(2H,s); 2.41(3H,s).

C) Synthesis of 2-acetyloxybenzoic acid 6-(nitrooxymethyl)-2-methylpyridinyl ester

To a solution of 2-acetyloxybenzoic acid 6-(chloromethyl)-2-methylpyridinyl ester (1.5 g, 4.7 mmol) in acetonitrile (20 ml) kept under stirring, silver nitrate (1.3 g, 7.65 mmol) is added. The solution is heated up to 80°C, maintaining it sheltered from light, under stirring for 30 hours. The formed silver chloride is filtered, the solvent is evaporated. The reaction raw product is purified by chromatography on silica gel eluting with n-hexane/ethyl acetate 7/3. 1.2 g of product as yellow oil are obtained.

<sup>1</sup>H-NMR (200MHz)(CDCl<sub>3</sub>): 8.10(1H,d); 7.74(1H,t); 7.57(1H,t); 7.42(1H,d); 7.33(2H,m); 7.11(1H,d); 5.60(2H,s); 5.42(2H,s); 2.41(3H,s).

D) Synthesis of 2-acetyloxybenzoic acid 6-(nitrooxymethyl)-2-methylpyridinyl ester hydrochloride

To a solution of 2-acetyloxybenzoic acid 6-(nitrooxymethyl)-2-methylpyridinyl ester (1 g, 2.88 mmoles) in ethyl acetate (20 ml) cooled at 0°C, a solution of ethyl acetate/HCl 5M is added dropwise under stirring. It is left for 1 hour at 0°C, then the temperature is let reach room values. The formed precipitate is filtered and washed with ethyl ether. 900 mg of solid product are obtained.


Elementary analysis

Calculated	C 50.21%	H 3.95%	N 7.31%	Cl 9.26%
Found	C 50.23%	H 3.97%	N 7.29%	Cl 9.20%

<sup>1</sup>H NMR (200MHz) (CDCl<sub>3</sub>): 8.10 (2H, m); 7.7 (1H, t); 7.56 (2H, d); 7.48 (1H, t); 7.30 (1H, d); 5.74 (2H, s); 5.43 (2H, s); 2.20 (3H, s).

EXAMPLE 2

Synthesis of 2-acetyloxybenzoic acid 6-(nitrooxymethyl)-2-methylpyridinyl ester nitrate of formula:



The 2-acetyloxybenzoic acid 6-(nitrooxymethyl)-2-methylpyridinyl ester nitrate is obtained starting from the 2-acetyloxybenzoic acid 6-(nitrooxymethyl)-2-methylpyridinyl ester isolated at step C) of Example 1.

To a solution of 2-acetyloxybenzoic acid-6-(nitrooxymethyl)-2-methylpyridinyl ester (1 g, 2.88 mmoles) in acetonitrile (10 ml) cooled at 0°C, a solution of nitric acid 65% (0.2 ml) in acetonitrile (2 ml) is added dropwise under stirring. It is left for 2 hours at 0°C, then the temperature is let reach the room temperature. The formed precipitate is



filtered and washed with ethyl ether. One gram of product as a solid is obtained.

#### Elementary analysis


Calculated C 46.95% H 3.69% N 10.26%

Found C 46.99% H 3.72% N 10.22%

<sup>1</sup>H NMR (200MHz) (CDCl<sub>3</sub>): 8.10 (1H, d); 7.9 (1H, t); 7.79(1H, t); 7.5 (3H, m); 7.30(1H, d); 5.73 (2H, s); 5.42 (2H, s); 2.20 (3H, s).

#### EXAMPLE 3

Synthesis of 2-acetyloxybenzoic acid 5-(nitrooxymethyl)-2-methylpyridinyl ester hydrochloride of formula:



The 2-acetyloxybenzoic acid 5-(nitrooxymethyl)-2-methylpyridinyl ester hydrochloride is synthesized according to the process described in Example 1, starting from acetyl salicylic acid and 2,5-bis(chloromethyl)pyridine.

#### A) Synthesis of 2,5-bis(chloromethyl)-pyridine

The compound is synthesized according to the process described in Example 1 A) starting from 2,5-pyridin-dimethanol, synthesized in its turn by reduction with NaBH<sub>4</sub> of di-ethyl-2,5-pyridin dicarboxylate in ethanol as described in patent JP 48029783.


#### Elementary analysis

Calculated C 50.21% H 3.95% N 7.32% Cl 9.26%

Found C 50.19% H 3.92% N 7.37% Cl 9.28%

EXAMPLE 4

Synthesis of 2-acetyloxybenzoic acid 3-(nitrooxymethyl)-2-methylpyridinyl ester hydrochloride of formula:



The 2-acetyloxybenzoic acid 3-(nitrooxymethyl)-2-methylpyridinyl ester hydrochloride is synthesized according to the process described in Example 1, starting from acetyl salicylic acid and 2,3-bis(chloromethyl)pyridine.

A) Synthesis of 2,3-bis(chloromethyl)-pyridine


The compound is synthesized according to the process described in Example 1 A) starting from 2,3-pyridine dimethanol, synthesized in its turn by reduction with  $\text{LiAlH}_4$  of di-methyl-2,3-pyridindicarboxylate in ethanol as described in J. Chem. Soc., Perkin Trans. 1 (1972), (20), 2485-2490.

Elementary analysis

Calculated	C 50.21%	H 3.95%	N 7.32%	Cl 9.26%
Found	C 50.25%	H 3.93%	N 7.30%	Cl 9.29%

EXAMPLE 5

Synthesis of 3-nitrooxymethylphenyl ester of the 2-acetoxybenzoic acid



A) Preparation of 3-hydroxymethylphenyl ester of the 2-acetoxybenzoic acid

3-hydroxymethylphenol (10 g, 0.08 moles) is dissolved in toluene (50 ml) containing triethylamine (9.8 g, 0.1 moles).

To the so obtained solution, a solution of the acetylsalicylic acid chloride (16 g, 0.08 moles) in toluene (50 ml) is added under stirring at the temperature of 5-10°C. The mixture is maintained at a temperature within the above range, under stirring for 2 hours, then poured into water and then extracted with dichloromethane (2 x 100 ml). The organic phase is separated, washed in sequence with a solution of potassium carbonate at 25% w/v, with water, with a 3% hydrochloric acid solution and finally again with water, then anhydriified with sodium sulphate and the solvent evaporated under reduced pressure. The residue is crystallized from isopropanol. 3-hydroxymethyl phenyl ester of the 2-acetoxybenzoic acid (45.8 g, 0.16 moles, yield 80%) is obtained.

M.p.: 79-81°C.

$^1\text{H}$  NMR( $\text{CDCl}_3$ )  $\delta$  (ppm): 2.29 (s, 3H); 4.71 (s, 2H); 7.07-8.2 (m, aromatics, 8H).

B) Nitration with fuming nitric acid, in the presence of sulphuric acid, of 3-hydroxymethylphenyl ester of the 2-acetoxybenzoic acid

A solution of fuming nitric acid (3.92 g, 62.2 mmol, 3 moles with respect to the moles of the hydroxyester under reaction) and sulphuric acid 96% (6.10 g, 62.2 mmol, 3 moles with respect to the moles of the hydroxyester under reaction) in dichloromethane (25 ml) is cooled to 0°C and added in one hour time under stirring and under nitrogen atmosphere, with a solution of 3-hydroxymethylphenyl ester of the 2-acetoxybenzoic acid (6 g, 20.7 mmol) in 25 ml of dichloromethane. The mixture is then diluted with dichloromethane (50 ml) and


poured into water and ice (100 g). The organic phase is separated, washed with water, anhydriified with sodium sulphate and the solvent evaporated under reduced pressure. The residue is crystallized from isopropanol obtaining the 3-nitrooxymethylphenyl ester of the 2-acetoxybenzoic acid (5.6 g, 17 mmoles, yield 82%).

M.p.: 61-62°C.

$^1\text{H}$  NMR( $\text{CDCl}_3$ )  $\delta$  (ppm): 2.31 (s, 3H); 5.44 (s, 2H); 7.16-8.22 (m, aromatics, 8H).

#### EXAMPLE 6

Synthesis of 2-(acetyloxy)benzoic acid 4-(nitrooxymethyl)phenyl ester



#### A) Synthesis of 2-(acetoxy)benzoic acid 3-(formyl)phenyl ester

To a mixture of 4-hydroxybenzaldehyde (20.75 g, 0.17 moles) and triethylamine (0.205 g, 2.4 mmoles) in methylene chloride (300 ml) kept under stirring, under nitrogen inert atmosphere, cooling at a temperature in the range -5°C-0°C, acetylsalicyloil chloride (41.25 g, 0.21 moles) is added in small aliquots in one hour. After 15 minutes water (250 ml) is added and the phases are separated. The aqueous phase is recovered and separately extracted with methylene chloride. The organic phases are mixed together, they are washed with a 5% carbonate solution (150 ml x 2) and then with water (125 ml x 2). The organic phase is anhydriified with sodium sulphate in the presence of decolorating carbon. It is filtered under vacuum and the solvent is evaporated under reduced pressure and at a bath temperature lower than 40°C, obtaining 48.2 g of

2-(acetyloxy)benzoic acid 4-(formyl)phenyl ester. The reaction raw product is used without further purification.

B) Synthesis of 2-(acetyloxy)benzoic acid 4-(hydroxymethyl)phenyl ester

A solution of 2-(acetyloxy)benzoic acid 4-(formyl)phenyl (48.2 g, 0.18 moles) ester in ethyl acetate (500 ml) is hydrogenated in the presence of 5% palladium on carbon (4 g) at room temperature, at hydrogen pressure of about 2.5 atm, under stirring. After 30 minutes the reactor is discharged, the catalyst is removed by filtration under nitrogen atmosphere.

The organic phase is washed with a 5% sodium bicarbonate solution and then with water. It is anhydriified with sodium sulphate and the solvent is evaporated at reduced pressure and the residue is used without further purification.

C) Synthesis of 2-(acetyloxy)benzoic acid 4-(chloromethyl)phenyl ester

To a mixture of 2-(acetyloxy)benzoic acid 4-(hydroxymethyl)phenyl (51.5 g, 0.18 moles) and  $\text{SOCl}_2$  (153 ml) kept under stirring, dimethylformamide (140 ml) is added at room temperature and it is left under stirring for one hour. At the end the thionyl chloride is evaporated at reduced pressure at a bath temperature lower than 40°C. The thionyl chloride traces in the compound are removed by treating the solid with toluene (60 x 2), which is then removed by evaporation at reduced pressure at a bath temperature lower than 40°C. The raw product is purified by crystallization with isopropyl ether to give 2-(acetyloxy)benzoic acid 4-(chloromethyl)phenyl ester (32.9 g, 0.10 moles). Yield 60%.

$^1\text{H}$  NMR: 8.25 (1H, d); 7.68 (1H, t); 7.43 (3H, m); 7.20 (3H, m); 4.60 (2H, s); 2.34 (3H, s).

D) Synthesis of 2-(acetyloxy)benzoic acid 4-(nitrooxymethyl)phenyl ester


To a solution of 2-(acetyloxy)benzoic acid 4-(chloromethyl)phenyl ester (32.9 g, 0.10 moles) in acetonitrile silver nitrate (22.2 g, 0.12 moles) is added under stirring, sheltered from light. The solution is heated at 70°C for 4 hours and then cooled to room temperature. The precipitate is filtered and the solvent evaporated at reduced pressure.

The residue is purified by chromatography on silica gel eluting with hexane/ethyl acetate (7:3 v/v) to give 2-(acetyloxy)benzoic acid 4-(nitrooxymethyl)phenyl ester (16.6 g, 0.05 moles). M.p. 86-88°C. Yield 50%.

<sup>1</sup>H NMR (CDCl<sub>3</sub>): 8.21 (1H, dd); 7.66 (1H, dt); 7.42 (3H, m); 7.20 (3H, m); 5.40 (2H, s), 2.25 (3H, s).

EXAMPLE 7

Synthesis of trans -3-[4-[2-(acetyloxy)benzoyloxy]-3-methoxyphenyl]-2-propenoic acid 4-(nitrooxy) butyl ester



A) Synthesis of trans -3-[4-hydroxy-3-methoxyphenyl]-2-propenoic acid 4-bromo butyl ester

To a solution of ferulic acid (10 g, 51.5 mmoles) in THF (400 ml) and cooled in a water bath, triphenylphosphine (27.01 g, 103 mmoles) and carbon tetrabromide (34.1 g, 103 mmoles) are in the order added. The mixture is kept under stirring for 5 hours at room temperature. When the reaction is ended, triphenylphosphine oxide is filtered and the solvent is evaporated at reduced pressure. The residue is purified by

chromatography on silica gel eluting with hexane/ethyl acetate (7:3 v/v). 7.75 g of trans -3-[4-hydroxy-3-methoxyphenyl]-2-propenoic acid 4-bromobutyl ester as a white solid are obtained. M.p. 86-89°C. Yield 46%.

B) Synthesis of trans -3-[4-[2-(acetyloxy) benzoyloxy]-3-methoxyphenyl]-2-propenoic acid 4-bromo butyl ester


To a solution of trans 3-[4-hydroxy-3-methoxyphenyl]-2-propenoic acid 4-bromo butyl ester (2 g, 6.1 mmol) in  $\text{CHCl}_3$  (20 ml) an acetylsalicylic acid mixture (1.1 g, 6.1 mmol) in DMF (2 ml) is added and it is cooled to 0°C, then DCC (1.50 g, 7.2 mmol) and DMAP (74 mg,  $6 \times 10^{-3}$  mmol) are added. It is left at the same temperature for 30 minutes and at room temperature for 16 hours. The precipitate is filtered and the solvent is evaporated at reduced pressure. The residue is dissolved in ethyl acetate (100 ml x 2 times) and washed with water and NaCl. The organic phase is anhydriified and the solvent is evaporated at reduce pressure.

The residue is purified by chromatography on silica gel eluting with hexane/ethyl acetate (8:2 v/v) to give the trans -3-[4-[2-(acetyloxy)benzoyloxy]-3-methoxyphenyl]-2-propenoic acid 4-bromo butyl ester (1.1 g, Yield 37%).

$^1\text{H}$  NMR  $\text{CDCl}_3$ : 8.25 (1H, d); 7.65 (2H, m); 7.40 (1H, t); 7.20 (4H, m); 6.39 (1H, d); 4.25 (2H, t); 3.85 (3H, s); 3.47 (2H, t); 2.29 (3H, s); 2.01 (2H, m); 1.89 (2H, m).

EXAMPLE 8

Synthesis of trans-3-[4-(4'-nitrooxybutyryloxy)-3-methoxyphenyl]-2-propenoic acid 4-(acetylamino)phenyl ester



A) Synthesis of trans-3-[4-acetyloxy-3-methoxyphenyl]-2-propenoic acid

To a solution of ferulic acid (5 g, 25.75 mmol) in pyridine (75 ml) cooled to 0°C and sheltered from light, acetic anhydride (13.14 g, 128.7 mmol) is added in small aliquots. When the addition is ended the temperature is let reach the room value maintaining the solution under magnetic stirring for 24 hours. HCl 18.5 % (160 ml) is added up to pH 2, one extracts with ethyl acetate and the organic phase is anhydriified and the solvent is evaporated at a reduced pressure. 5.15 g of trans-3-[4-acetyloxy-3-methoxyphenyl]-2-propenoic acid are obtained as a white solid. M.p. 199-205°C. Yield 85%.

B) Synthesis of trans-3-[4-acetyloxy-3-methoxyphenyl]-2-propenoyl chloride

To a suspension of trans-3-[4-acetyloxy-3-methoxyphenyl]-2-propenoic acid (4 g, 16.93 mmol) in toluene (70 ml) and dimethylformamide (10 ml) cooled in an ice bath, oxalyl chloride (4.30 g, 33.87 mmol) is dropped. The mixture is maintained under stirring at 0°C for 1 hour then the temperature is let reach the room value and it is left for 2 hours. The solvent is removed at reduced pressure and the raw product is used without further purification.

C) Synthesis of trans-3-[4-acetyloxy-3-methoxyphenyl]-2-propenoic acid 4-(acetylamino)phenyl ester

To a solution of paracetamol (2.56 g, 16.92 mmol) in pyridine (20 ml) cooled in an ice bath trans-3-[4-acetyloxy-3-methoxyphenyl]-2-propenoyl chloride (4.31 g, 16.92 mmol) dissolved in acetone (45 ml) is dropped. The mixture is maintained under stirring in ice for 3 hours then it is poured into water (300 ml) and the precipitate is filtered and triturated with hexane to give trans-3-[4-acetyloxy-3-methoxyphenyl]-2-propenoic acid 4-(acetylamino)phenyl ester (4.38 g) as an orange solid. M.p. 246-250°C. Yield 70%.



D) Synthesis of trans-3-[4-hydroxy-3-methoxyphenyl]-2-propenoic acid 4-(acetylamino)phenyl ester

To a solution of trans-3-[4-acetyloxy-3-methoxyphenyl]-2-propenoic acid 4-(acetylamino)phenyl ester (4.2 g, 11.37 mmols) in methanol (650 ml) and tetrahydrofuran (850 ml), potassium carbonate (9.11 g, 65.95 mmols) dissolved in water (50 ml) is added and it is left under stirring at room temperature for 2 hours. The precipitate is filtered and the solution is brought to pH 6 with HCl 5% (15 ml). One extracts with ethyl acetate and the organic phase is anhydriified and removed from the solvent at reduced pressure. The raw product is purified by chromatography on silica gel eluting with chloroform/methanol (9/0.5 v/v). Trans-3-[4-hydroxy-3-methoxyphenyl]-2-propenoic acid 4-(acetylamino)phenyl ester (2.1 g) is obtained as a white solid. M.p. 185-195°C. Yield 56%.

<sup>1</sup>H NMR (CDCl<sub>3</sub>): 10 (1H, s); 9.8 (1H, s); 7.8 (1H, d); 7.7 (2H, d); 7.3 (2H, d); 7.1 (2H, d); 6.9 (1H, d); 6.7 (1H, d); 3.8 (3H, s); 2 (3H, s).

E) Synthesis of trans-3-[4-(4'-bromobutyryloxy)-3-methoxyphenyl]-2-propenoic acid 4-(acetylamino)phenyl ester

To a solution of trans-3-[4-hydroxy-3-methoxyphenyl]-2-propenoic acid 4-(acetylamino)phenyl ester (1.6 g, 4.8 mmols) in pyridine (12 ml) cooled in ice bath, 4-bromobutyryl chloride (1.3 g, 7.2 mmols) dissolved in acetone (15 ml) is dropped and it is maintained under stirring for 7 hours. It is poured into water and ice, the precipitate is filtered and treated with hexane. Trans-3-[4-(4'-bromobutyryloxy)-3-methoxyphenyl]-2-propenoic acid 4-(acetyl amino)phenyl ester (1.8 g) is obtained. Yield 67%.

F) Synthesis of trans-3-[4-(4'-nitrooxybutyryloxy)-3-methoxyphenyl]-2-propenoic acid 4-(acetylamino)phenyl ester


To a solution of trans-3-[4-(4'-bromobutyryloxy)-3-methoxyphenyl]-2-propenoic acid 4-(acetylamino)phenyl ester

(1.8 g, 3.78 mmoles) in acetonitrile (100 ml), silver nitrate (1.28 g, 7.56 mmoles) is added sheltered from light. It is left at 80°C for 13 hours then the precipitate is filtered. The raw product is purified by chromatography on silica gel eluting with hexane/ethyl acetate (3/7 v/v). Trans-3-[4-(4'-nitrooxy-butyryloxy)-3-methoxyphenyl]-2-propenoic acid 4-(acetylamino)phenyl ester is obtained.

<sup>1</sup>H NMR (CDCl<sub>3</sub>): 7.8 (1H, d); 7.5 (3H, m); 7.1 (5H, m); 6.5 (1H, d); 4.6 (2H, t); 3.8 (3H, s); 2.7 (2H, t); 2.17 (5H, m).

#### EXAMPLE 9

Synthesis of 4-nitrooxybutanoic acid 4'-acetylamino phenyl ester



#### A) Preparation of 4-bromobutanoic acid 4'-acetylamino phenyl ester

To a solution of 4-bromobutyric acid (4.6 g, 27.6 mmoles) in chloroform (45 ml) and N,N-dimethylformamide (20 ml), paracetamol (4.17 g, 27.6 mmoles), N,N'-dicyclohexyl carbodiimide (8.42 g, 40.8 mmoles) and 4-dimethyl aminopyridine (0.15 g, 1.25 mmoles) are added. The reaction mixture is kept under stirring at room temperature for 72 hours, filtered and evaporated under vacuum. The reaction raw product is treated with ethyl acetate and washed with brine and then with water. The organic phase is anhydriified with sodium sulphate and then evaporated under vacuum.

The residue is purified by chromatography on silica gel eluting with n-hexane/ethyl acetate 4/6 (v/v ratio). 5.33 g of the product as a white solid ar obtained.

M.p.= 108-110°C.

B) Preparation of 4-nitrooxybutanoic acid 4'-acetylamino phenyl ester

To a solution of 4-bromobutanoic acid 4'-acetylamino phenyl ester (5.33 g, 17.8 mmol) in acetonitrile (80 ml) silver nitrate (4.56 g, 26.9 mmol) is added. The reaction mixture is heated for 16 hours in absence of light at 80°C, then cooled to room temperature, filtered for removing the silver salts, and evaporated at reduced pressure. The residue is purified by chromatography on silica gel, eluting with n-hexane/ethyl acetate 4/6. 4.1 g of the product as a white solid are obtained.


M.p. = 80-83°C.

Elementary analysis:	C	H	N
calc.	51.07%	4.99%	9.92%
found	51.06%	5.00%	9.90%

<sup>1</sup>H NMR (CDCl<sub>3</sub>): 7.55 (1H, s); 7.49 (2H, d); 7.02 (2H, d); 4.58 (2H, t); 2.71 (2H, t); 2.19 (2H, m); 2.14 (3H, s).

EXAMPLE 10

Synthesis of 4-(nitrooxymethyl)-benzoic acid 4'-acetylamino phenyl ester



A) Preparation of 4-(chloromethyl)-benzoic acid 4'-acetylamino phenyl ester

To a solution of paracetamol (2 g, 13.23 mmol) in tetrahydrofuran (80 ml), triethylamine (1.34 g, 13.23 mmol) and 4-(chloromethyl)-benzoylchloride (2.5 g, 13.23 mmol) are added. The reaction mixture is kept under stirring at room temperature for 24 hours, then the solvent is evaporated at reduced pressure and the reaction raw product is purified by chromatography on silica gel, eluting with methylene

chloride/methanol 20/0.5 (v/v ratio) to give 2.6 g of 4-(chloromethyl)-benzoic acid 4-acetyl amino phenyl ester. (Yield 65%)

$^1\text{H}$  NMR ( $\text{CDCl}_3$ ): 8.1 (2H, d); 7.69 (2H, d); 7.45 (2H, d); 7.02 (2H, d); 4.9 (2H, s); 2.14 (3H, s).


B) Preparation of 4-(nitrooxymethyl)-benzoic acid 4-acetyl amino phenyl ester

To a solution of 4-(chloromethyl)-benzoic acid 4-acetyl amino phenyl ester (2 g, 6.6 mmol) in acetonitrile (80 ml) silver nitrate (2.24 g, 13.18 mmol) is added. The reaction mixture is heated for 20 hours in absence of light at  $60^\circ\text{C}$ , then cooled to room temperature, filtered for removing the silver salts, and evaporated at reduced pressure. The residue is purified by chromatography on silica gel, eluting with n-hexane/ethyl acetate 3/7 (v/v ratio). 1.13 g of 4-(nitrooxymethyl)-benzoic acid 4-acetyl amino phenyl ester are obtained. (Yield 52%)

$^1\text{H}$  NMR ( $\text{CDCl}_3$ ): 8.1 (2H, d); 7.69 (2H, d); 7.45 (2H, d); 7.02 (2H, d); 5.74 (2H, s); 2.14 (3H, s).

EXAMPLE 11

Preparation of 3-(nitrooxymethyl)-benzoic acid 4-acetyl amino phenyl ester



A) Preparation of 3-(chloromethyl)-benzoic acid 4-acetyl amino phenyl ester

To a solution of paracetamol (2 g, 13.23 mmol) in tetrahydrofuran (80 ml), triethylamine (1.34 g, 13.23 mmol) and 4-(chloromethyl)-benzoyl chloride (2.5 g, 13.23 mmol) are added. The reaction mixture is kept under stirring at room temperature for 24 hours, then the solvent is evaporated at

reduced pressure and the reaction raw product is purified by chromatography on silica gel, eluting with methylene chloride/methanol 20/0.5 (v/v ratio) to give 2.9 g of 3-(chloromethyl)-benzoic acid 4-acetylamino phenyl ester. (Yield 73%)

$^1\text{H}$  NMR ( $\text{CDCl}_3$ ): 8.1 (1H, s); 8.02 (1H, d); 7.77 (1H, d); 7.65 (1H, m); 7.45 (2H, d); 7.02 (2H, d); 4.9 (2H, s); 2.14 (3H, s).


B) Preparation of 3-(nitrooxymethyl)-benzoic acid 4-acetylamino phenyl ester

To a solution of 3-(chloromethyl)-benzoic acid 4-acetylamino phenyl ester (2.5 g, 8.2 mmol) in acetonitrile (80 ml) silver nitrate (2.8 g, 16.4 mmol) is added. The reaction mixture is heated for 20 hours in absence of light at  $60^\circ\text{C}$ , then cooled to room temperature, filtered for removing the silver salts, and evaporated at reduced pressure. The residue is purified by chromatography on silica gel, eluting with n-hexane/ethyl acetate 3/7 (v/v ratio). 1.5 g of 3-(nitrooxymethyl)-benzoic acid 4-acetylamino phenyl ester are obtained. (Yield 55%)

$^1\text{H}$  NMR ( $\text{CDCl}_3$ ): 8.1 (1H, s); 8.02 (1H, d); 7.77 (1H, d); 7.65 (1H, m); 7.45 (2H, d); 7.02 (2H, d); 5.74 (2H, s); 2.14 (3H, s).

EXAMPLE 12

Synthesis of 2-(nitrooxymethyl)-benzoic acid 4-acetylamino phenyl ester



A) Preparation of 2-(chloromethyl)-benzoylchloride

To thionyl chloride (35 ml) cooled at  $0^\circ\text{C}$  with ice bath, the 2-hydroxymethylbenzoic acid (4 g, 26.3 mmol) is added. The temperature is let reach the room value and the mixture is left under stirring for 2 hours, then it is evaporated at

reduced pressure and treated 3 times with chloroform for completely removing the thionyl chloride. The reaction raw product is used without further purification.

B) Preparation of 2-(chloromethyl)-benzoic acid 4-acetyl amino phenyl ester

To a solution of paracetamol (2 g, 13.23 mmols) in tetrahydrofuran (80 ml), triethylamine (1.34 g, 13.23 mmols) and 2-(chloromethyl)-benzoylchloride (2.5 g, 13.23 mmols) are added. The reaction mixture is kept under stirring at room temperature for 24 hours, then the solvent is evaporated at reduced pressure and the reaction raw product is purified by chromatography on silica gel, eluting with methylene chloride/methanol 20/0.5 (v/v ratio) to give 1.9 g of 2-(chloromethyl)-benzoic acid 4-acetyl amino phenyl ester. (Yield 47%)

<sup>1</sup>H NMR (CDCl<sub>3</sub>): 8.22 (1H, d); 7.41 (5H, m); 7.02 (2H, d); 4.9 (2H, s); 2.14 (3H, s).


C) Preparation of 2-(nitrooxymethyl)-benzoic acid 4-acetyl amino phenyl ester

To a solution of 2-(chloromethyl)-benzoic acid 4-acetyl amino phenyl ester (1.5 g, 4.9 mmols) in acetonitrile (80 ml) silver nitrate (1.68 g, 9.8 mmols) is added. The reaction mixture is heated for 20 hours in absence of light at 60°C, then cooled to room temperature, filtered for removing the silver salts, and evaporated at reduced pressure. The residue is purified by chromatography on silica gel, eluting with n-hexane/ethyl acetate 3/7 (v/v ratio). 0.77 g of 2-(nitrooxymethyl)-benzoic acid 4-acetyl amino phenyl ester are obtained. (Yield 48%)

<sup>1</sup>H NMR (CDCl<sub>3</sub>): 8.22 (1H, d); 7.41 (5H, m); 7.02 (2H, d); 5.40 (2H, s); 2.14 (3H, s).

EXAMPLE 13

Synthesis of 2-acetylamino-3-(4-nitrooxybutyryl)-3-mercapto-propionic acid 4-acetylamino phenyl ester



A) Preparation of 2-acetylamino-3-(4-bromobutyryl)-3-mercaptopropionic acid

To a solution of 4-bromobutyric acid (3 g, 17.9 mmol) in 35 ml of chloroform, carbonyl-diimidazol (2.9 g, 17.9 mmol) is added and it is left under stirring at room temperature for one hour. Then N-acetylcysteine (2.9 g, 17.9 mmol); sodium ethylate (40 mg, 0.58 mmol) and dimethylformamide (5 ml) are added and the mixture is left under stirring at room temperature for 15 hours. Diluted HCl is added and the organic phase is separated. The aqueous phase brought to pH 3-3.5 is extracted with ethyl acetate. The organic phases mixed together are anhydriified with sodium sulphate and evaporated at reduced pressure. The reaction raw product is purified by chromatography on silica gel, eluting with chloroform/ethyl acetate 3/7 (v/v ratio). 2.06 g of 2-acetylamino-3-(4-bromobutyryl)-3-mercapto-propionic acid are obtained. (Yield 37%)

$^1\text{H}$  NMR ( $\text{CDCl}_3$ ): 10.0 (1H, s); 6.89 (1H, d); 4.78 (1H, m); 3.40 (4H, m); 2.77 (2H, t); 2.18 (2H, m); 2.04 (3H, s).

B) Preparation of 2-acetylamino-3-(4-bromobutyryl)-3-mercaptopropionic acid 4-acetylamino phenyl ester

To a solution of 2-acetylamino-3-(4-bromobutyryl)-3-mercaptopropionic acid in chloroform (20 ml) and dimethylformamide (20 ml), cooled at  $0^\circ\text{C}$  with ice bath, paracetamol (1 g, 7.2 mmol), dicyclohexylcarbodiimide (1.17 g, 5.6 mmol) and N,N-dimethyl aminopyridine (90 mg) are added. The

temperature is let reach the room value and the mixture is left under stirring for 24 hours. The precipitate is filtered and the organic phase is washed with water. The organic phase is anhydried with sodium sulphate and the solvent is evaporated at reduced pressure. The raw product has been purified by chromatography on silica gel eluting with methylene chloride/methanol 20/0.5 (v/v ratio). 0.6 g of 2-acetylamino-3-(4-bromobutyryl)-3-mercaptopropionic acid 4-acetylamino phenyl ester are obtained. (Yield 32%)

$^1\text{H}$  NMR ( $\text{CDCl}_3$ ): 7.45 (2H, d); 7.00 (2H, m); 4.80 (1H, m); 3.52 (2H, t); 3.32 (2H, d); 2.7 (2H, t); 2.1 (2H, m); 2.00 (3H, s).


C) Preparation of 2-acetylamino-3-(4-nitrooxy butyryl)-3-mercaptopropionic acid 4-acetylamino phenyl ester

To a solution of 2-acetylamino-(4-bromobutyryl)-3-mercaptopropionic acid 4-acetylamino phenyl ester (0.5 g, 1.26 mmol) in acetonitrile (40 ml) silver nitrate (0.43 g, 2.52 mmol) is added. The reaction mixture is heated for 20 hours in absence of light at 80°C, then cooled to room temperature, filtered for removing the silver salts, and evaporated at reduced pressure. The residue is purified by chromatography on silica gel, eluting with n-hexane/ethyl acetate 3/7 (v/v ratio). 0.31 g of 2-acetylamino-3-(4-nitrooxybutyryl)-3-mercaptopropionic acid 4-acetylamino phenyl ester are obtained. (Yield 63%)

$^1\text{H}$  NMR ( $\text{CDCl}_3$ ): 7.45 (2H, d); 7.00 (2H, m); 4.80 (1H, m); 4.57 (2H, t); 3.32 (2H, d); 2.7 (2H, t); 2.1 (2H, m); 2.00 (3H, s).

EXAMPLE 14

Synthesis of 3-[(2-nitrooxy)ethyloxy]propanoic acid 4-acetylamino phenyl ester





A) Preparation of 3-[(2-hydroxy)ethyloxy]propanoic acid 4-acetylamino phenyl ester

To a solution of paracetamol (5 g, 33.6 mmol) in chloroform (80 ml) and dimethylformamide (80 ml), cooled at 0°C with ice bath, 3-[(2-hydroxy)ethyloxy]propanoic acid (3 g, 22.38 mmol), dicyclohexylcarbodiimide (6.9 g, 33.6 mmol) and dimethylaminopyridine (0.2 g, 1.68 mmol) are added. The temperature is let reach the room value and the mixture is left under stirring for 24 hours. The precipitate is filtered and the organic phase is washed with water and extracted with chloroform. The organic phase is anhydried with sodium sulphate and the solvent evaporated at reduced pressure. The raw product is purified by chromatography on silica gel eluting with methylene chloride/methanol 20/0.5 (v/v ratio). 1.3 g of 3-[(2-hydroxy) ethyloxy]propanoic acid 4-acetylamino phenyl ester are obtained. (Yield 33%)

<sup>1</sup>H NMR (CDCl<sub>3</sub>): 7.45 (2H, d); 7.02 (2H, d); 4.40 (2H, t); 3.75 (6H, m); 2.14 (3H, s).

B) Preparation of 3-[(2-iodo)ethyloxy]propanoic acid 4-acetylamino phenyl ester

To a solution of 3-[(2-hydroxy)ethyloxy]propanoic acid 4-acetylamino phenyl ester (1.5 g, 5.6 mmol), imidazol (0.57 g, 8.4 mmol) and triphenylphosphine (1.9 g, 7.28 mmol) in ether (15 ml) and acetonitrile (10 ml) cooled at 0°C with ice bath, iodine (1.99 g, 7.84 mmol) is added and it is left under stirring at 0°C for 2 hours. Then the temperature is let reach the room value, hexane is added, the precipitate is filtered and the solvent is evaporated at reduced pressure. The raw product is purified by chromatography on silica gel eluting with hexane/ethyl acetate 3/7 (v/v ratio). 1 g of 3-[(2-iodo)ethyloxy]propanoic acid 4-acetylamino phenyl ester is obtained.

(Yield 48%)

$^1\text{H}$  NMR ( $\text{CDCl}_3$ ): 7.45 (2H, d); 7.02 (2H, d); 4.40 (2H, t); 3.75 (4H, t); 3.54 (2H, t); 2.14 (3H, s).


C) Preparation of 3-[(2-nitrooxy)ethyloxy]propanoic acid 4-acetylamino phenyl ester

To a solution of 3-[(2-iodo)ethyloxy]propanoic acid 4-acetylamino phenyl ester (1 g, 2.64 mmol) in acetonitrile (40 ml) silver nitrate (0.9 g, 5.28 mmol) is added. The reaction mixture is heated for 5 hours in absence of light at  $60^\circ\text{C}$ , then cooled to room temperature, filtered for removing the silver salts, and evaporated at reduced pressure. The residue is purified by chromatography on silica gel, eluting with n-hexane/ethyl acetate 3/7 (v/v ratio). 0.46 g of 3-[(2-nitrooxy) ethyloxy]propanoic acid 4-acetylamino phenyl ester are obtained. (Yield 56%)

$^1\text{H}$  NMR ( $\text{CDCl}_3$ ): 7.45 (2H, d); 7.02 (2H, d); 4.58 (2H, t); 4.40 (2H, t); 3.75 (4H, t); 2.14 (3H, s).

EXAMPLE 15

Synthesis of 2-hydroxybenzoic acid 3-(nitrooxymethyl) phenyl ester



To a solution of 2-(acetyloxy)benzoic acid 3-(nitrooxymethyl)phenylester (2 g, 6.04 mmol), obtained as described in Example 5, in tetrahydrofuran (10 ml), methanol (5 ml) and water (4 ml), imidazol (0.04 g, 0.6 mmol) is added. The mixture is left under stirring at room temperature for 20 days, then the solvent is evaporated at reduced pressure, the residue is treated with ethyl acetate and washed with water.


The organic phase is anhydried with sodium sulphate and the solvent is evaporated at reduced pressure. The reaction raw product is purified by chromatography on silica gel using

as eluent hexane/ethyl acetate (9/1 v/v) to give 2-hydroxybenzoic acid 3-(nitrooxymethyl)phenylester (0.8 g). Yield 46%.

$^1\text{H}$  NMR ( $\text{CDCl}_3$ ): 10.46 (1H, s); 8.13 (1H, dd); 7.56 (2H, m); 7.34 (3H, m); 7.05 (2H, m); 5.51 (2H, s).

#### EXAMPLE 16

Synthesis of trans-3-[4-[ $\alpha$ -methyl-[4-(-2-methylpropyl)benzene] acetyloxy]-3-methoxyphenyl]-2-propenoyl 4-(nitrooxy) butyl ester having formula:



#### A) Synthesis of trans-3-[4-[ $\alpha$ -methyl-[4-(-2-methylpropyl)benzene] acetyloxy]-3-methoxyphenyl]-2-propenoic acid

To a solution of  $\alpha$ -methyl-[4-(2-methylpropyl)benzene]acetic acid (5.03 g, 24.4 mmol) in tetrahydrofuran (100 ml) and N,N-dimethylformamide (5 ml), 1,1-carbonyldiimidazole (4.25 g, 24.8 mmol) is added. After 1 hour the obtained solution is treated with ferulic acid (4.90 g, 25 mmol), sodium ethylate (89 mg) is added and it is left at room temperature under stirring for 12 hours. The reaction mixture is washed with HCl 5%, then with water and at last with brine. The organic phase is anhydriified with sodium sulphate and evaporated at reduced pressure.

The obtained residue is purified by chromatography on silica gel, eluting with ethyl acetate/n-hexane 7/3. 5.1 g of trans-3-[4-[ $\alpha$ -methyl-[4-(-2-methylpropyl)benzene] acetyl]-3-methoxyphenyl]-2-propenoic acid are obtained as a white solid having m.p. 131-137°C.

$^1\text{H}$ -NMR ( $\text{CDCl}_3$ ) : 7.72 (1H, d), 7.32 (2H, dd), 7.26 (1H, m), 7.16-7.07 (4H, m), 6.98 (1H, d), 6.37 (1H, d), 3.99 (1H, q),

3.73 (3H, s), 2.47 (2H, d), 1.88 (1H, m), 1.63 (3H, d), 0.92 (6H, d).

B) Synthesis of trans-3-[4-[ $\alpha$ -methyl-[4-(-2-methylpropyl)benzene]acetyloxy]-3-methoxyphenyl]-2-propenoyl 4-bromobutyl ester

To a solution of trans-3-[4-[ $\alpha$ -methyl-[4-(2-methylpropyl)benzene]acetyloxy]-3-methoxyphenyl]-2-propenoic acid (5.33 g, 14 mmol) in N,N-dimethylformamide (130 ml), sodium ethylate (1.2 g, 16 mmol) is added under stirring. After 1 hour to the obtained mixture 1,4-dibromobutane (10 g, 46 mmol) is added and the mixture is let react at room temperature for 12 hours. The reaction mixture is washed with 5% HCl, then with water and at last with brine, the organic phase is anhydried with sodium sulphate and evaporated at reduced pressure. The obtained residue is purified by chromatography on silica gel eluting with n-hexane/ethyl acetate 8/2. 4.46 g of trans-3-[4-hydroxy-[ $\alpha$ -methyl-[4-(-2-methylpropyl)benzene]acetyl]-3-methoxyphenyl]-2-propenoyl 4-bromobutyl ester are obtained.

C) Synthesis of trans-3-[4-[ $\alpha$ -methyl-[4-(-2-methylpropyl)benzene]acetyloxy]-3-methoxyphenyl]-2-propenoyl 4-(nitrooxy) butyl ester

To a solution of trans-3-[4-[ $\alpha$ -methyl-[4-(-2-methylpropyl)benzene]acetyloxy]-3-methoxyphenyl]-2-propenoyl 4-bromobutyl ester (4 g, 7.72 mmol) in acetonitrile (70 ml) silver nitrate (2.58 g, 15 mmol) is added. The reaction mixture is heated under reflux for 2 hours sheltered from light. At the end the formed salt is removed by filtration and the solution is evaporated at reduced pressure. The recovered residue is purified by chromatography on silica gel, eluting with n-hexane/ethyl acetate 8/2. 2.4 g of trans-3-[4-[ $\alpha$ -methyl-[4-(-2-methylpropyl)benzene]acetyloxy]-3-methoxyphenyl]-2-propenoyl 4-(nitrooxy) butyl ester are obtained as oil.

$^1\text{H}$ -NMR ( $\text{CDCl}_3$ ): 7.62 (1H, d), 7.32 (2H, d), 7.15 (2H, d), 7.16-7.05 (2H, m), 6.96 (1H, d), 6.35 (1H, d), 4.51 (2H, t), 4.24 (2H, t), 3.99 (1H, q), 3.74 (3H, s), 2.48 (2H, d), 1.89-1.83 (5H, m), 1.62 (3H, d), 0.92 (6H, d).


Elementary analysis:

Calculated C: 64.91%      H: 6.66%      N: 2.82%

Found      C: 64.83%      H: 6.52%      N: 2.69%

#### EXAMPLE 17

Synthesis of trans-3-[4-[2-fluoro- $\alpha$ -methyl-(1,1'-biphenyl)-4-acetyloxy]-3-methoxyphenyl]-2-propenoyl 4-(nitrooxy) butyl ester having formula:



The compound is synthesized according to the process described in Example 16. The process total yield is 32%. The substance appears as an amorphous solid.

$^1\text{H}$ -NMR ( $\text{CDCl}_3$ ): 7.40-7.25 (9H, m), 7.07-7.01 (2H, d), 6.98 (1H, m), 6.38 (1H, d), 4.44 (2H, t), 4.46 (2H, t), 4.21 (2H, t), 4.04 (1H, q), 3.73 (3H, s), 1.72 (4H, m), 1.65 (3H, d).


Elementary analysis:

Calculated C: 64.79%      H: 5.25%      N: 2.62%      F: 3.53%

Found      C: 64.85%      H: 5.31%      N: 2.74%      F: 3.48%

EXAMPLE 18

Syntheis of (Z)-5-fluoro-2-methyl-1-[[4-(methylsulphinyl) phenyl]methylene]-1H-indene-3-acetic acid (4-nitrooxy)butyl ester



A) Synthesis of (Z)-5-fluoro-2-methyl-1-[[4-(methylsulphinyl) phenyl]methylene]-1H-indene-3-acetic acid 4-bromobutyl ester

To a solution of Sulindac (5.17 g, 14.5 mmols) in dimethylformamide (50 ml) EtONa (1.18 g, 16.4 mmols) is added. The reaction mixture is kept under stirring for one hour, then 1,4-dibromobutane dissolved in dimethylformamide (20 ml) is added.

The reaction mixture is kept under stirring at room temperature for 8 hours, ethyl acetate is added and the mixture is washed with water. The organic phase is anhydriified with sodium sulphate and the solvent is evaporated at reduced préssure.

The reaction raw product is purified by chromatography on silica gel eluting with a mixture of hexane/ethyl acetate (3/7 v/v). Cis-5-fluoro-2-methyl-1-[[4-(methylsulphinyl) phenyl]methylene]-1H-indene-3-acetic acid 4-bromobutyl ester (3.8 g) is obtained as a yellow solid. Yield 55%.

B) Synthesis of (Z)-5-fluoro-2-methyl-1-[[4-(methylsulphinyl) phenyl]methylene]-1H-indene-3-acetic acid (4-nitrooxy)butyl ester


To a solution of cis-5-fluoro-2-methyl-1-[[4-(methyl sulphinyl)phenyl]methylene]-1H-indene-3-acetic acid 4-bromo-

butyl ester (3.8 g, 7.7 mmol) in acetonitrile (50 ml)  $\text{AgNO}_3$  (3.9 g, 22.3 mmol) is added sheltered from light. The mixture is heated at  $80^\circ\text{C}$  for 48 hours, then the precipitate is filtered and the solvent is evaporated. The reaction raw product is purified by chromatography on silica gel eluting with a mixture of hexane/ethyl acetate (1/9 v/v). (Z)-5-fluoro-2-methyl-1-[[4-(methylsulphonyl) phenyl]methylene]-1H-indene-3-acetic acid (4-nitrooxy)butyl ester (2.6 g) is obtained as a yellow solid. Yield 68%.

$^1\text{H}$  NMR ( $\text{CDCl}_3$ ): 7.78-7.62 (4H, m); 7.17 (2H, m); 6.88 (1H, dd); 6.60-6.50 (1H, m); 4.39 (2H, t); 4.16 (2H, t); 3.57 (2H, s); 2.79 (3H, s); 2.20 (3H, s); 1.79-1.61 (4H, m).

#### EXAMPLE 19

Synthesis of (Z)-5-fluoro-2-methyl-1-[[4-(methylsulphonyl) phenyl]methylene]-1H-indene-3-acetic acid 6(nitrooxymethyl)-2-methyl pyridinyl ester



The (Z)-5-fluoro-2-methyl-1-[[4-(methylsulphonyl)phenyl]methylene]-1H-indene-3-acetic acid 6(nitrooxymethyl)-2-methyl pyridinyl ester is synthesized according to the process described in Example 1, starting from (Z)-5-fluoro-2-methyl-1-[[4-(methylsulphonyl)phenyl]methylene]-1H-indene-3-acetic acid and 2,6-bis (chloromethyl)pyridine. Total yield of the process 20%.


Elementary analysis:

Calculated C 57.09% N 5.12% F 3.47% Cl 6.48% S 5.86%

Found            C 57.19%    N 4.51%    F 3.43%    Cl 6.51%    S 5.84%

### EXAMPLE 20

Synthesis of 2-acetyloxybenzoic acid 2-(nitrooxymethyl)phenyl ester



The 2-acetyloxybenzoic acid 2-(nitrooxymethyl)phenyl ester is synthesized according to the process described in Example 6, starting from acetylsalicylic acid and 2-hydroxybenzaldehyde. Total yield of the process 68%.

<sup>1</sup>H NMR (CDCl<sub>3</sub>): 8.22 (1H, dd); 7.68 (1H, dt); 7.35 (6H, m); 5.40 (2H, s); 2.30 (3H, s).

## PHARMACOLOGICAL EXAMPLES

EXAMPLE F1

Determination of the capability of the compounds of the invention to protect the animals from the liver injury induced by Concanavalin A.

The model in vivo used in the present example has been described in Tiegs G, Hentschel J, A Wendel. A T cell-dependent experimental liver injury in mice induced by Concanavalin A. J. Clin. Invest. 1992; 90:196-203.

The animals (rats of Swiss stock weighing about 20 g) are divided in groups of at least No. 10 animals for group.

The animals receive concanavalin and solvent (treated control group), solvent (polyethylene glycol 400 - untreated control group), concanavalin and tested compound dissolved in the solvent (treated groups).



Rats are treated intravenously with concanavalin A (0.3 mg/rat), and after 5 minutes they receive by intraperitoneal injection the tested compounds, at the doses reported in Table 1, dissolved in polyethylenglycol 400.

Eight hours after the concanavalin A injection all the animals were sacrificed and the blood collected and examined. The data, reported in Table 1, are expressed as value of the plasmatic glutamic-pyruvic transaminase percentage of the animals treated with the tested compound with respect to the animals of the treated control group.

The results show that the compounds according to the invention protect from the liver injury induced by concanavalin A, while the native or precursor compounds even worsen the liver injury.

#### EXAMPLE F2

Determination of the antiproliferative activity of the compounds of the invention in cancerous cells.

Human adenocarcinoma (HT29) cells taken from colon affected by cancerous process were transferred into plates with 24 wells containing a cellular culture medium formed by 10% of foetal bovine serum, penicillin (50 U/ml), streptomycin (50 mg/ml) and PEG 400 (polyethylenglycol). After 24 hours a part of the plates is inoculated with the tested compounds dissolved in the carrier (PEG 400). 96 hours after the inoculation of the compounds the cellular growth was measured by haemocytometer. The results, reported in Table 2, are expressed as percentage of the cellular proliferation with respect to the controls.

The obtained results show that the compounds of the invention are much more effective in inhibiting the proliferation of the cancerous cells with respect to the corresponding native compounds.

**EXAMPLE F3**

Determination of the antiproliferative activity of the compounds of the invention in cancerous epithelial cells of bladder and prostate.

The experiment was carried out by using three human epithelial cellular lines of the prostate cancer (PNT1A; LLNCaP; PC3) and three human epithelial cellular lines of the bladder cancer (T24; 647V; 1207), the various types of cellular lines are identified on the basis of the characteristics, in particular of the aggressiveness, of the cancerous process.

The cancerous cells are sown, with an initial concentration of 20,000 cells/cm<sup>2</sup>, in plates having 96 wells with a cellular culture medium RPMI added with foetal bovine serum 5% and L-Glutamine 1%. Solutions in dimethylsulphoxide of the tested compounds at three different concentrations (10<sup>-6</sup> M; 10<sup>-5</sup> M; 10<sup>-4</sup> M) or the carrier (DMSO 1<sup>0</sup>/100) are added to the culture medium. 4 days after the treatment the cellular growth was measured by the method with MTT (3-[4,5-dimethylthiazol-2-yl]-2,5-diphenyltetrazolium bromide) described by Turner in: Turner T., Chen P., Goodly L.J., Wells A. Clin. Exp. Metastasis 1996, 14, 409-418. The results, reported in Table 3, are expressed as inhibition percentage of the cellular proliferation determined by measuring the cellular proliferation in the cellular cultures treated with the tested compounds with respect to that measured in cellular cultures treated with dimethylsulphoxide 1<sup>0</sup>/100.

The results reported in Table 3 show that the nitrooxybutyl ester of sulindac (Ex. 18) at the 10<sup>-5</sup> M concentration has a strong inhibitory effect on the proliferation of all kinds of cancerous cells examined; the compound of Ex. 16, reported in the Table with the simplified denomination of nitrooxybutyl ester of the ibuprofen der. with ferulic ac. and the compound of Ex. 17, reported in the Table

with the simplified denomination of nitrooxybutyl ester of the flurbiprofen der. with ferulic ac., are active in very aggressive prostate and bladder tumours, as it is shown by the results obtained on the cellular lines LNCaP and PC3, and 647V, 1207. The compound of Ex. 7, reported in the Table with the simplified denomination of nitrooxybutyl ester of the aspirin der. with ferulic ac. is active, at  $10^{-5}$  concentrations, in prostate tumours as shown by the results obtained on the cellular lines LNCaP and PC3.

#### EXAMPLE F4

Determination in vitro of the effect of the compounds of the invention on the thymidine incorporation in human Adenocarcinoma HT29 cells.

Human adenocarcinoma cells are sown on plates having 24 wells ( $2.5 \times 10^5$  cells/plate) with a standard culture medium.

After 24 hours some plates are inoculated with the tested compounds dissolved in dimethylsulphoxide at a  $200 \mu\text{M}$  concentration and others are treated with the tested compounds dissolved in dimethylsulphoxide at a  $200 \mu\text{M}$  concentration in the presence of a solution of cisplatinum  $25 \mu\text{M}$ . After 15 hours of incubation the plates are put into contact with a solution of  $^3\text{H}$ -thymidine  $1 \mu\text{Ci/mol}$  (RAS. 3,000 Ci/mol).

The cell monolayer of each plate is first washed twice with a cold saline buffer, then treated with TCA (trichloroacetic acid) at 5% for 10 minutes and then washed three times with absolute alcohol. The cells of each well are dissolved in  $500 \mu\text{l}$  of NaOH  $0,1\text{N}$  and the incorporated radioactivity is determined by scintillation counting.

The obtained results are reported in Table 4 and expressed as percentage of  $^3\text{H}$ -Thymidine incorporated in the cells treated with the tested compounds and in the presence of Cisplatinum, considering equal to 100 the amount of  $^3\text{H}$ -

Timidine incorporated in the cells treated only with Cisplatinum.

Table 1

Activity in the prevention of the liver injury induced by Concavalin A		
Treatment	Dose (mg/kg)	Liver injury %
Treated controls	-	100
Untreated controls	-	2
Paracetamol	500	160
Nitrooxybutyl ester of the Paracetamol der. with ferulic acid (Ex. 8)	500	8
Paracetamol nitrooxybutyl ester (Ex. 9)	500	10
Aspirin	300	120
Aspirin ester with 5- nitrooxymethyl-2-hydroxymethyl pyridine (Ex. 3)	300	5
Aspirin ester with 3- nitrooxymethyl-2-hydroxymethyl pyridine (Ex. 4)	300	7
Sulindac	200	115
Ester sulindac with 6- nitrooxymethyl-2-hydroxymethyl pyridine (Ex. 19)	200	23
Sulindac 4-nitrooxybutyl ester (Ex. 18)	200	18

Table 2

Activity in vitro on the proliferation of cancerous cells		
Treatment	Concentration ( $\mu$ M)	Proliferation %
Controls	-	100
Aspirin	500	100
Nitrooxybutyl ester of the aspirin der. with ferulic acid (Ex. 7)	300	50
Aspirin ester with 3- nitrooxymethylphenol (Ex. 5)	300	40
Aspirin ester with 4- nitrooxymethylphenol (Ex. 6)	10	0
Aspirin ester with 6- nitrooxymethyl-2-hydroxymethyl pyridine (Ex. 1)	10	0
Aspirin ester with 2- nitrooxymethylphenol (Ex. 20)	20	50
Sulindac	50	100
Sulindac 4-nitrooxybutyl ester (Ex. 18)	50	0

Table 3


Determination in vitro of the inhibitory effect on the proliferation of cancerous human cells of prostate cancer and of bladder cancer of the compounds of the invention							
Compounds	Conc. (M)	Inhibition of the proliferative activity ( % )					
		Human epithelial cells of prostate cancer			Human epithelial cells of bladder cancer		
		PNT1 A	LNCaP	PC3	T24	647V	1207
Sulindac Nitrooxybutyl ester (Ex. 18)	$10^{-6}$	3	17	5	0	9	0
	$10^{-5}$	38	74	68	82	80	74
	$10^{-4}$	81	88	74	93	92	88
Nitrooxybutyl ester of the Ibuprofen der. with Ferulic acid (Ex. 16)	$10^{-6}$	0	8	4	0	0	2
	$10^{-5}$	4	33	9	0	0	0
	$10^{-4}$	20	60	47	22	45	43
Nitrooxybutyl ester of the Flurbiprofen der. with Ferulic acid (Ex. 17)	$10^{-6}$	0	1	8	0	0	0
	$10^{-5}$	2	26	20	0	13	0
	$10^{-4}$	13	58	53	23	41	34
Nitrooxybutyl ester of the aspirin der. With Ferulic acid (Ex. 7)	$10^{-6}$	0	20	1	2	0	4
	$10^{-5}$	0	47	30	0	0	24
	$10^{-4}$	72	81	69	55	50	82

Table 4

Determination in vitro of the effect of some compounds on the thymidine incorporation in human adenocarcinoma cells			
Treatment	Conc. ( $\mu$ M)	Without Cisplatinium	With 25 $\mu$ M Cisplatinium
Controls	-	438	100
Carrier (DMSO)	-	438	100
Salicylic acid Comparison	200	438	100
3-(nitrooxymethyl) phenyl ester of Salicylic acid (Ex.15)	200	246	50
Acetylsalicylic acid Comparison	200	438	100
3-(nitrooxymethyl) phenyl ester of Acetylsalicylic acid (Ex. 5)	200	192	46

## CLAIMS

1. Use for preparing drugs for pre-cancer or cancer diseases on an inflammatory basis of nitroderivatives or salts thereof having the followin general formula (I):




wherein:

p is an integer equal to 1 or 0;

A = R-T<sub>1</sub>-, wherein

R is the radical of a precursor drug and it has the following formulas:



(AI)

wherein


s is an integer and it is 1 or 0;

R<sub>AI</sub> is H, CH<sub>3</sub>;

R<sub>1</sub> is OCOR<sub>3</sub>, R<sub>3</sub> being a C<sub>1</sub>-C<sub>5</sub> linear or branched radical, NHCOR<sub>3</sub>, wherein R<sub>3</sub> has the above meaning, or R<sub>1</sub> is OH, CH<sub>2</sub>CH(CH<sub>3</sub>)<sub>2</sub>, phenyl, benzoyl, 4,6-dichlorophenylamino;

R<sub>6</sub> is H, or one halogen atom, preferably fluorine;


or R<sub>1</sub> and R<sub>6</sub>, when are located in the adjacent positions 4 and 5 of the aromatic ring of formula (AI), form the radical of following formula (AIa):



(AIa)



or R can be the following formula:



(AII)

$T_1 = (CO)_t$  or  $(X)_{t'}$ , wherein  $X = O, S, NR_{1c}, R_{1c}$  is H or a linear or branched alkyl, having from 1 to 5 carbon atoms,  $t$  and  $t'$  are integers and equal to zero or 1, with the proviso that  $t = 1$  when  $t' = 0$ ;  $t = 0$  when  $t' = 1$ ;


$X_1 = -T_B-Y-T_{BI}-$  wherein

$T_B$  and  $T_{BI}$  are equal or different;

$T_B = (CO)$  when  $t = 0$ ,  $T_B = X$  when  $t' = 0$ ,  $X$  being as above;

$T_{BI} = (CO)_{tx}$  or  $(X)_{txx}$ , wherein  $tx$  and  $txx$  have the value of 0 or 1; with the proviso that  $tx = 1$  when  $txx = 0$ ; and  $tx = 0$  when  $txx = 1$ ;  $X$  is as above;

$Y$  is a bivalent linking group selected from the following:



(II)

wherein:

$nIX$  is an integer in the range 0-3, preferably

1;


$n_{IIX}$  is an integer in the range 1-3, preferably

1;

$R_{TIX}$ ,  $R_{TIX'}$ ,  $R_{TIIIX}$ ,  $R_{TIIIX'}$ , equal to or different from each other are H or a  $C_1$ - $C_4$  linear or branched alkyl; preferably  $R_{TIX}$ ,  $R_{TIX'}$ ,  $R_{TIIIX}$ ,  $R_{TIIIX'}$  are H;


$Y^3$  is a saturated, unsaturated or aromatic heterocyclic ring, having 5 or 6 atoms, containing one or two nitrogen atoms,

- an alkylene group  $R'$  wherein  $R'$  is a  $C_1$ - $C_{20}$  linear or branched when possible, preferably having from 2 to 6 carbon atoms, optionally substituted with one or more of the following groups:  
-NHCOR<sub>3</sub>, wherein  $R_3$  is as above, -NH<sub>2</sub>, -OH or
- a cycloalkylene having from 5 to 7 carbon atoms, optionally substituted with side chains  $R'$ ,  $R'$  being as above, one or more carbon atoms of the cycloalkylene ring can optionally be substituted by heteroatoms; or




(III)

wherein  $n_3$  is an integer from 0 to 3 and  $n_{3'}$  is an integer from 1 to 3;



(IV)

wherein  $n_3$  and  $n_3'$  have the above meaning,




(V)


wherein

$R_4$  is hydroxy, hydrogen,  $R_5O$ - alkoxy wherein  $R_5$  is a  $C_1$ - $C_{10}$  linear or branched or cyclic alkyl group, preferably  $R_5$  is a methyl group;


$R_2$  is a  $C_2$ - $C_{10}$  linear or branched alkenylene group which can contain one or more double bonds, preferably  $R_2$  is the ethenylene group ( $-\text{CH}=\text{CH}-$ ); or




(VI)



(VII)



(VIII)



(IX)

wherein  $\text{R}_{1f} = \text{H}, \text{CH}_3$  and  $nf$  is an integer from 0 to 6; preferably from 0 to 4;

$\text{L} = \text{covalent bond}$ , or  $\text{L} = \text{X}$ ,  $\text{X}$  being as above, or  $\text{L} = \text{CO}$ ;

$\text{W} = \text{Y}_T\text{O}$  wherein  $\text{Y}_T$  has the same meanings of  $\text{Y}$  and  $\text{Y}_T$  in the compound of formula (I) is equal to or different from  $\text{Y}$ .

2. Use according to claim 1, wherein the diseases on an inflammatory basis are those affecting the digestive apparatus, preferably the intestinal tract, such as colites, gastrites, enterites, duodenites; besides hepatopathies and tumoral processes related to diseases on an inflammatory basis.
3. Use according to claims 1-2, wherein:
 

when in formula (AI),  $\text{R}_1$  is an acetyloxy group in position 2 of the ring,  $s = 0$  and  $\text{R}_6 = \text{H}$  and the free valence of the radical  $\text{R}$  is saturated with the  $-\text{COOH}$  group, the compound is known as Acetylsalicylic Acid,

when in formula (AI)  $\text{R}_1$  is a hydroxyl group in position 2 of the ring,  $s = 0$  and  $\text{R}_6 = \text{H}$  and the free valence of the radical  $\text{R}$  is saturated with a  $-\text{COOH}$  group, the compound is known as Salicylic Acid,

when in formula (AI)  $\text{R}_1$  is an acetylamino group in position 4 of the ring,  $s = 0$  and  $\text{R}_6 = \text{H}$  and the free valence is saturated with a  $-\text{OH}$  group, the compound is known as Paracetamol,

when in formula (AI)  $\text{R}_1$  is  $\text{CH}_2\text{CH}(\text{CH}_3)_2$  in position 4 of the ring,  $s = 1$ ,  $\text{R}_{At} = \text{CH}_3$  and  $\text{R}_6 = \text{H}$  and the free valence is

saturated with a COOH group, the compound is known as Ibuprofen,

when in formula (AI)  $R_1$  is phenyl and is in position 4 of the ring,  $s = 1$ ,  $R_{At} = CH_3$  and  $R_6 = F$  in position 3 and the free valence is saturated with a -COOH group, the compound is known as Flurbiprofen,


when in formula (AII) the free valence is saturated with the -COOH group, the compound is known as Sulindac,


when in formula (AI)  $R_1$  and  $R_6$  are the radical of formula (AIIa) and they are connected with the positions 4 and 5 of the ring,  $s = 1$ ,  $R_{At} = CH_3$ ,  $R_6 = H$  and the free valence is saturated with a -COOH group, the compound is known as Naproxen,

when in formula (AI)  $R_1$  is a benzoyl radical in position 5 of the aromatic ring,  $s = 1$ ,  $R_{At} = CH_3$ ,  $R_6 = H$  and the free valence is saturated with a -COOH group, the compound is known as Ketoprofen,

when in formula (AI)  $R_1 = 2,6$ -diclorofenilammino in position 2 of the ring,  $s = 1$ ,  $R_{At} = H$ ,  $R_6 = H$  and the free valence is saturated with a -COOH group, the compound is known as Diclofenac.

4. Use according to claims 1-3; wherein  $Y^3$  in formula (II) of the linking group Y of  $X_1$  in formula (I) is selected from the following bivalent radicals:





5. Use according to claim 4, wherein  $Y^3$  is an aromatic ring having 6 atoms, containing one nitrogen atom, said aromatic ring having the two free valences respectively in the positions 2 and 6, or 2 and 3 or 2 and 5 with respect to the heteroatom.
6. Use according to claims 4-5, wherein  $Y^3$  is Y12 (pyridyl).
7. Use according to claims 1-6, wherein in formula (I):
  - when in formula (AI)  $s = 0$  and  $R_6 = H$ :
  - R is a radical of formula (AI) wherein the substituent  $R_1$  is in position 2 of the aromatic ring, and it is selected between acetyloxy or hydroxyl, or it is an acetamino group and then it is in position 4;  $-T_1-T_8-$  is a  $-CO-O-$  or  $-O-OC-$  ester group; Y of the radical  $X_1$  is a bivalent linking group selected from the following:
    - a radical of formula (III) as above, wherein,  $n_3 = 0$  and  $n_3' = 1$ ,
    - a radical of formula (II) as above wherein  $Y^3$  is Y12 as above defined,
    - a radical of formula (VIII) as above wherein  $R_{1f}$  is hydrogen and  $n_f = 1$ ;
  - $T_{B1} = -O-$ , L = covalent bond;  $p = 0$ ;
  - R is a radical of formula (AI) wherein the substituent  $R_1$  is in position 2 of the aromatic ring, and it is selected between acetyloxy or hydroxyl, or it is an acetamino group and then it is in position 4;  $-T_1-T_8-$  is a  $-CO-O-$  or  $-O-OC-$  ester group; Y of the radical  $X_1$  is a bivalent linking group having formula (V) as

above wherein  $R_4$  is a methoxyl group and  $R_2 = -CH=CH-$ ;  $-T_{B1}-L-$  is a  $-CO-O-$  or  $-O-OC-$  ester group;  $p = 1$ ;  $W = YO$  wherein  $Y$  is  $-(CH_2)_4-$  or  $-(CH_2)_3-$ ;

- $R$  is a radical of formula (AI) wherein the substituent  $R_1$  is in position 4 of the aromatic ring, and it is acetylamino;  $-T_1-T_B = -O-CO-$ ;  $Y$  of the radical  $X_1$  is  $-(CH_2)_3-$ ;  $-T_{B1}-L = -O-$  ( $L =$  covalent bond);  $p = 0$ ;
- $R$  is a radical of formula (AI) wherein the substituent  $R_1$  is in position 4 of the aromatic ring, and it is acetylamino;  $-T_1-T_B = -O-CO-$ ;  $Y$  of the radical  $X_1$  is an ethylene group substituted with an acetylamino group:  $-CH(NHCOCH_3)-CH_2-$ ;  $-T_{B1}-L = -S-CO-$ ;  $p = 1$ ;  $W = YO$  wherein  $Y$  is  $-(CH_2)_3-$ ;

when in formula (AI)  $s = 1$ :

- $R$  is a radical of formula (AI),  $R_6 = H$  or  $F$  in position 3 of the ring,  $R_1 = CH_2CH(CH_3)_2$  or phenyl in position 4,  $-T_1-T_B = -CO-O-$  ester group;  $Y$  of the radical  $X_1$  is a bivalent linking group having formula (V) as above wherein  $R_4$  is a methoxyl group and  $R_2 = -CH=CH-$ ;  $-T_{B1}-L$  is a  $-CO-O-$  ester group;  $p = 1$ ;  $W = YO$  wherein  $Y$  is  $-(CH_2)_3-$ ;

- when in formula (I)  $R$  is a radical of formula (AII),  $-T_1-T_B = -CO-O-$ ;  $Y$  of the radical  $X_1$  is a bivalent linking group selected from the following:

- a radical of formula (II) as above wherein  $Y3$  is  $Y12$  as above,
- $-(CH_2)_4-$ ;
- $-T_{B1} = -O-$ ,  $L =$  covalent bond;  $p = 0$ .

8. Use according to claims 1-7, wherein the compounds are selected from the following:

- when the drug radical has formula (AI) the compounds of formula (I) are the following:

2-(acetyloxy)benzoic acid 3-(nitrooxymethyl)phenyl ester,  
 2-(hydroxy)benzoic acid 3-(nitrooxymethyl)phenyl ester,  
 2-(acetyloxy)benzoic acid 4-(nitrooxymethyl)phenyl ester,  
 2-(hydroxy)benzoic acid 4-(nitrooxymethyl)phenyl ester,  
 2-(acetyloxy)benzoic acid 2-(nitrooxymethyl)phenyl ester,  
 2-(hydroxy)benzoic acid 2-(nitrooxymethyl)phenyl ester,  
 2-(acetyloxy)benzoic acid 6-(nitrooxymethyl)-2-methyl  
 pyridinyl ester hydrochloride, or nitrate,  
 2-(hydroxy)benzoic acid 6-(nitrooxymethyl)-2-methyl  
 pyridinyl ester hydrochloride, or nitrate,  
 2-(acetyloxy)benzoic acid 5-(nitrooxymethyl)-2-methyl  
 pyridinyl ester hydrochloride, or nitrate,  
 2-(hydroxy)benzoic acid 5-(nitrooxymethyl)-2-methyl py-  
 ridinyl ester hydrochloride or nitrate,  
 2-(acetyloxy)benzoic acid 3-(nitrooxymethyl)-2-methyl  
 pyridinyl ester hydrochloride, or nitrate,  
 2-(hydroxy)benzoic acid 3-(nitrooxymethyl)-2-methyl py-  
 ridinyl ester hydrochloride, or nitrate,  
 trans-3-[4-[2-acetyloxybenzoyloxy]-3-methoxy phenyl]-2-  
 propenoic acid 4-(nitrooxy)butyl ester,  
 trans-3-[4-[2-hydroxybenzoyloxy]-3-methoxyphenyl]-2-  
 propenoic acid 4-(nitrooxy)butyl ester,  
 4-(nitrooxy)butanoic acid 4-(acetilamino)phenyl ester,  
 trans-3-[4-(4'-nitrooxybutyryloxy)-3-methoxy phenyl]-2-  
 propenoic acid 4-(acetilamino)phenyl ester,  
 3-(nitrooxymethyl)-benzoic acid 4-(acetilamino)phenyl  
 ester,  
 4-(nitrooxymethyl)-benzoic acid 4-(acetilamino)phenyl  
 ester,  
 2-(nitrooxymethyl)-benzoic acid 4-(acetilamino)phenyl  
 ester,



5-(nitrooxymethyl)pyridin-2-carboxylic acid 4-(acetyl amino)phenyl ester,

6-(nitrooxymethyl)-pyridin-2-carboxylic acid 4-(acetyl amino)phenyl ester,

3-(nitrooxymethyl)-pyridin-2-carboxylic acid 4-(acetyl amino)phenyl ester,

5-(nitrooxymethyl)-pyridin-2-carboxylic acid 4-(acetyl amino)phenyl ester,

5-(nitrooxymethyl)pyridin-2-acetic acid 4-(acetyl amino)phenyl ester,

6-(nitrooxymethyl)pyridin-2-acetic acid 4-(acetyl amino)phenyl ester,

3-(nitrooxymethyl)pyridin-2-acetic acid 4-(acetyl amino)phenyl ester,

3-[(2-nitrooxy)ethyloxy]propanoic acid 4-(acetyl amino)phenyl ester,

trans 3-[4-(4'-nitrooxybutyryloxy)-3-methoxy] phenyl-2-propenoic acid 4-(acetylamino)phenyl ester,

2-(acetylamino)-3-(4-nitrooxybutyryl)-3-mercaptopropanoic acid 4-(acetylamino)phenyl ester,

trans-3-[4-[ $\alpha$ -methyl-4-(2-methylpropyl)phenyl acetyloxy]-3-methoxyphenyl]-2-propenoic acid 4-nitrooxybutyl ester,

trans 3-[4-[2-fluoro- $\alpha$ -methyl(1,1'-biphenyl)-acetyloxy]-3-methoxyphenyl]-2-propenoic acid 4-nitrooxy butyl ester,

(S) 6-methoxy- $\alpha$ -methyl-2-naphtalenacetic acid 2-methoxy-4-[(1E)-3-[4-(nitrooxy)butoxy]-3-oxo-1-propenyl]phenyl ester,

(S) 6-methoxy- $\alpha$ -methyl-2-naphtalenacetic acid 3-(nitrooxy methyl)phenyl ester,

(S) 6-methoxy- $\alpha$ -methyl-2-naphtalenacetic acid 6-(nitrooxy methyl)-2-methylpyridinyl ester,

(S,S)-N-acetyl-S-(6-methoxy- $\alpha$ -methyl-2-naphtaleneacetyl)  
cysteine 4-(nitrooxy)butyl ester,  
2-[(2,6-dichlorophenyl)amino]benzeneacetic acid 6-(nitro  
oxymethyl)-2-methylpyridinil ester chloridrate,

- when the drug radical has formula AII the compounds  
of formula (I) are the following:

(Z)-5-fluoro-2-methyl-1-[[4-(methylsulphinyl)phenyl]  
methylene]-1H-inden-3-acetic acid 4-(nitrooxy)butyl  
ester,

(Z)-5-fluoro-2-methyl-1-[[4-(methylsulphinyl)phenyl]  
methylene]-1H-inden-3-acetic acid 6-(nitrooxy-  
methyl)-2-methyl pyridinyl ester hydrochloride, or  
nitrate,

(Z)-5-fluoro-2-methyl-1-[[4-(methylsulphinyl)phenyl]  
methylene]-1H-inden-3-acetic acid 5-(nitrooxy-  
methyl)-2-methyl pyridinyl ester hydrochloride, or  
nitrate,

(Z)-5-fluoro-2-methyl-1-[[4-(methylsulphinyl)phenyl]  
methylene]-1H-inden-3-acetic acid 3-(nitrooxy-  
methyl)-2-methyl pyridinyl ester hydrochloride, or  
nitrate.

9. Use according to claims 1-8, wherein for the prevention  
and/or treatment of tumoral diseases the compounds of  
claims 1-8 are administered in combination with  
chemotherapeutic drugs or in the radiotherapeutic  
treatment.
10. Compounds according to claim 8.

## INTERNATIONAL SEARCH REPORT

International Application No

PCT/EP 01/11664

## A. CLASSIFICATION OF SUBJECT MATTER

IPC 7 C07C203/04 C07C233/54 C07C323/60 C07D201/02 C07C317/46  
 A61K31/21 C07D213/34 A61K31/44

According to International Patent Classification (IPC) or to both national classification and IPC

## B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 7 C07D A61K C07C

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

EPO-Internal, WPI Data, PAJ, CHEM ABS Data, BEILSTEIN Data

## C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	WO 00 51988 A (NICOX SA ;DEL SOLDATO PIERO (IT); BENEDINI FRANCESCA (IT)) 8 September 2000 (2000-09-08)	1-10
Y	see the whole document, especially the examples 1,2 etc and the claim 9	1-10
X	EP 0 722 434 A (NICOX SA) 24 July 1996 (1996-07-24)	1-3
Y	see whole document	1-10
X	US 6 040 341 A (DEL SOLDATO PIERO ET AL) 21 March 2000 (2000-03-21)	1-3,8
Y	see examples and whole document	1-10
	--- -/--	

☒ Further documents are listed in the continuation of box C.☒ Patent family members are listed in annex.

## \* Special categories of cited documents :

\*A\* document defining the general state of the art which is not considered to be of particular relevance

\*E\* earlier document but published on or after the International filing date

\*L\* document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)

\*O\* document referring to an oral disclosure, use, exhibition or other means

\*P\* document published prior to the international filing date but later than the priority date claimed

\*T\* later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

\*X\* document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

\*Y\* document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.

\*Z\* document member of the same patent family

Date of the actual completion of the international search

1 March 2002

Date of mailing of the international search report

11/03/2002

Name and mailing address of the ISA

European Patent Office, P.B. 5816 Patentlaan 2  
 NL - 2280 HV Rijswijk  
 Tel (+31-70) 340-2040, Tx. 31 651 epo nl,  
 Fax: (+31-70) 340-3016

Authorized officer

Scruton-Evans, I

## INTERNATIONAL SEARCH REPORT

International Application No

PCT/EP 01/11664

## C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	US 5 861 426 A (DEL SOLDATO PIERO ET AL) 19 January 1999 (1999-01-19)	1-3,8
Y	see the Tables 1-4 and the whole document	1-10
P,X	WO 01 04082 A (NICOX SA ;CASTALDI GRAZIANO (IT); RAZZETTI GABRIELE (IT); OLDANI E) 18 January 2001 (2001-01-18) the whole document	1-3,8
P,X	WO 01 12584 A (NICOX SA ;DEL SOLDATO PIERO (IT)) 22 February 2001 (2001-02-22) see page 1, last lines, page 19, general formula and example 1 and example 21	1-10
P,X	WO 00 61541 A (NICOX SA ;DEL SOLDATO PIERO (IT)) 19 October 2000 (2000-10-19) see page 2 and claim 1	1-10
X	WO 00 44705 A (NICOX SA ;DEL SOLDATO PIERO (IT); GARUFI MICHELE (IT)) 3 August 2000 (2000-08-03) see examples	1-3,8
P,X	WO 01 00563 A (NICOX SA ;ANTOGNAZZA PATRIZIA (IT); BENEDINI FRANCESCA (IT)) 4 January 2001 (2001-01-04) the whole document	1-3,10

# INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No

PCT/EP 01/11664

Patent document cited in search report		Publication date	Patent family member(s)	Publication date
• WO 0051988	A	08-09-2000	IT MI990413 A1 AU 3158800 A BR 0008582 A WO 0051988 A1 EP 1154999 A1	04-09-2000 21-09-2000 13-02-2002 08-09-2000 21-11-2001
EP 0722434	A	24-07-1996	GB 2283238 A IT 1269735 B AU 678063 B2 AU 7809294 A BR 9407749 A DE 69412109 D1 DE 69412109 T2 DK 722434 T3 EP 0722434 A1 JP 9503214 T RU 2136653 C1 SI 722434 T1 US 5700947 A US 5780495 A AT 168986 T CA 2173582 A1 WO 9509831 A1 ES 2120070 T3 HK 1004916 A1 HU 74446 A2 AT 184589 T AU 702662 B2 AU 2215695 A BR 9507634 A CA 2190087 A1 DE 69512232 D1 DE 69512232 T2 DK 759899 T3 WO 9530641 A1 EP 0759899 A1 ES 2139199 T3 GR 3032078 T3 HU 75961 A2 JP 9512798 T RU 2145595 C1 SI 759899 T1 US 5861426 A	03-05-1995 15-04-1997 15-05-1997 01-05-1995 12-02-1997 03-09-1998 21-01-1999 16-11-1998 24-07-1996 31-03-1997 10-09-1999 31-12-1998 23-12-1997 14-07-1998 15-08-1998 13-04-1995 13-04-1995 16-10-1998 11-12-1998 30-12-1996 15-10-1999 25-02-1999 29-11-1995 23-09-1997 16-11-1995 21-10-1999 24-02-2000 20-12-1999 16-11-1995 05-03-1997 01-02-2000 31-03-2000 28-05-1997 22-12-1997 20-02-2000 31-12-1999 19-01-1999
US 6040341	A	21-03-2000	IT MI952263 A1 AT 193883 T AU 709338 B2 AU 7495096 A BR 9611175 A DE 69608916 D1 DE 69608916 T2 DK 871606 T3 EP 0871606 A1 GR 3033827 T3 JP 11514636 T SI 871606 T1 WO 9716405 A1 ES 2148808 T3	30-04-1997 15-06-2000 26-08-1999 22-05-1997 30-03-1999 20-07-2000 11-01-2001 31-07-2000 21-10-1998 31-10-2000 14-12-1999 31-08-2000 09-05-1997 16-10-2000

# INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No

PCT/EP 01/11664

Patent document cited in search report		Publication date	Patent family member(s)	Publication date
US 6040341	A		HU 9802986 A2 PT 871606 T	28-04-1999 30-11-2000
US 5861426	A	19-01-1999	IT 1269735 B IT 1274609 B AU 702662 B2 AU 2215695 A BR 9507634 A DE 69512232 D1 DE 69512232 T2 DK 759899 T3 EP 0759899 A1 GR 3032078 T3 JP 9512798 T RU 2145595 C1 SI 759899 T1 AT 168986 T AT 184589 T AU 678063 B2 AU 7809294 A BR 9407749 A CA 2173582 A1 CA 2190087 A1 DE 69412109 D1 DE 69412109 T2 DK 722434 T3 WO 9509831 A1 WO 9530641 A1 EP 0722434 A1 ES 2120070 T3 ES 2139199 T3 HU 74446 A2 HU 75961 A2 JP 9503214 T RU 2136653 C1 SI 722434 T1 US 5700947 A US 5780495 A	15-04-1997 18-07-1997 25-02-1999 29-11-1995 23-09-1997 21-10-1999 24-02-2000 20-12-1999 05-03-1997 31-03-2000 22-12-1997 20-02-2000 31-12-1999 15-08-1998 15-10-1999 15-05-1997 01-05-1995 12-02-1997 13-04-1995 16-11-1995 03-09-1998 21-01-1999 16-11-1998 13-04-1995 16-11-1995 24-07-1996 16-10-1998 01-02-2000 30-12-1996 28-05-1997 31-03-1997 10-09-1999 31-12-1998 23-12-1997 14-07-1998
WO 0104082	A	18-01-2001	IT MI991517 A1 AU 5684500 A WO 0104082 A1	09-01-2001 30-01-2001 18-01-2001
WO 0112584	A	22-02-2001	IT MI991817 A1 AU 6567000 A WO 0112584 A2	12-02-2001 13-03-2001 22-02-2001
WO 0061541	A	19-10-2000	IT MI990752 A1 AU 4547400 A BR 0009703 A WO 0061541 A2 EP 1169298 A2 NO 20014928 A	13-10-2000 14-11-2000 08-01-2002 19-10-2000 09-01-2002 13-12-2001
WO 0044705	A	03-08-2000	IT MI990134 A1 AU 2664500 A BR 0007643 A WO 0044705 A1	26-07-2000 18-08-2000 16-10-2001 03-08-2000

# INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No

PCT/EP 01/11664

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
WO 0044705 A		EP 1147074 A1	24-10-2001
WO 0100563 A	04-01-2001	IT MI991402 A1	27-12-2000
		AU 6264400 A	31-01-2001
		WO 0100563 A1	04-01-2001

## FURTHER INFORMATION CONTINUED FROM PCT/ISA/ 210

Continuation of Box I.2

Claims Nos.: 1-2,4-7,9

Present claims 1-2,4-7,9 relate to an extremely large number of possible compounds. Support within the meaning of Article 6 PCT and/or disclosure within the meaning of Article 5 PCT is to be found, however, for only a very small proportion of the compounds claimed. In the present case, the claims so lack support, and the application so lacks disclosure, that a meaningful search over the whole of the claimed scope is impossible. Consequently, the search has been carried out for those parts of the claims which appear to be supported and disclosed, namely those parts relating to the claims 3, 8 and 10 and the examples.

The applicant's attention is drawn to the fact that claims, or parts of claims, relating to inventions in respect of which no international search report has been established need not be the subject of an international preliminary examination (Rule 66.1(e) PCT). The applicant is advised that the EPO policy when acting as an International Preliminary Examining Authority is normally not to carry out a preliminary examination on matter which has not been searched. This is the case irrespective of whether or not the claims are amended following receipt of the search report or during any Chapter II procedure.